US20230273221A1 - Method relating to myostatin pathway inhibition - Google Patents
Method relating to myostatin pathway inhibition Download PDFInfo
- Publication number
- US20230273221A1 US20230273221A1 US18/312,879 US202318312879A US2023273221A1 US 20230273221 A1 US20230273221 A1 US 20230273221A1 US 202318312879 A US202318312879 A US 202318312879A US 2023273221 A1 US2023273221 A1 US 2023273221A1
- Authority
- US
- United States
- Prior art keywords
- myostatin
- muscle
- level
- follistatin
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010056852 Myostatin Proteins 0.000 title claims abstract description 243
- 230000037361 pathway Effects 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 69
- 230000005764 inhibitory process Effects 0.000 title description 9
- 102000004472 Myostatin Human genes 0.000 title 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims abstract description 267
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 81
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 78
- 210000003205 muscle Anatomy 0.000 claims abstract description 73
- 108010014612 Follistatin Proteins 0.000 claims abstract description 63
- 102000016970 Follistatin Human genes 0.000 claims abstract description 63
- 239000003112 inhibitor Substances 0.000 claims abstract description 43
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 34
- 230000009885 systemic effect Effects 0.000 claims abstract description 34
- 238000001964 muscle biopsy Methods 0.000 claims abstract description 24
- 238000001574 biopsy Methods 0.000 claims abstract description 15
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 38
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 33
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 31
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 27
- 108020004999 messenger RNA Proteins 0.000 claims description 26
- 101150088768 mtm-1 gene Proteins 0.000 claims description 22
- 230000007170 pathology Effects 0.000 claims description 22
- 210000002027 skeletal muscle Anatomy 0.000 claims description 22
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 21
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 21
- 201000008319 inclusion body myositis Diseases 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108010069091 Dystrophin Proteins 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 102000001039 Dystrophin Human genes 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 208000032978 Structural Congenital Myopathies Diseases 0.000 claims description 7
- 230000001195 anabolic effect Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 201000003728 Centronuclear myopathy Diseases 0.000 claims description 4
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 2
- 208000010316 Myotonia congenita Diseases 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 230000001010 compromised effect Effects 0.000 claims description 2
- 201000011474 congenital myopathy Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000000488 activin Substances 0.000 abstract description 14
- 108010059616 Activins Proteins 0.000 abstract description 11
- 102100026818 Inhibin beta E chain Human genes 0.000 abstract description 11
- 108010023082 activin A Proteins 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 29
- 108050006583 Growth/differentiation factor 8 Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000013459 approach Methods 0.000 description 14
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 12
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000013607 AAV vector Substances 0.000 description 9
- 101100228739 Danio rerio mstnb gene Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 9
- 101150048453 MSTN gene Proteins 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000037444 atrophy Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 208000018360 neuromuscular disease Diseases 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000029578 Muscle disease Diseases 0.000 description 6
- 108090000697 Myotubularin Proteins 0.000 description 6
- 208000013896 centronuclear myopathy X-linked Diseases 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 102000004128 Myotubularin Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 206010028417 myasthenia gravis Diseases 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- -1 FSTN Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001132874 Homo sapiens Myotubularin Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 208000021642 Muscular disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037257 muscle growth Effects 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 3
- 108010052946 Activin Receptors Proteins 0.000 description 3
- 102000018918 Activin Receptors Human genes 0.000 description 3
- 101150080985 GDF11 gene Proteins 0.000 description 3
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028311 Muscle hypertrophy Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 102100033817 Myotubularin Human genes 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 208000025033 X-linked centronuclear myopathy Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229950006326 bimagrumab Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 230000012042 muscle hypertrophy Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 102220005395 rs33991223 Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 101000825933 Homo sapiens Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Proteins 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 2
- 102100022770 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Human genes 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000003019 respiratory muscle Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000022379 skeletal muscle tissue development Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- WWFDJIVIDXJAQR-FFWSQMGZSA-N 1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(O)(=S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](COP(O)(=S)O[C@@H]%11[C@@H](COP(O)(=S)O[C@@H]%12[C@@H](COP(O)(=S)O[C@@H]%13[C@@H](COP(O)(=S)O[C@@H]%14[C@@H](COP(O)(=S)O[C@@H]%15[C@@H](COP(O)(=S)O[C@@H]%16[C@@H](COP(O)(=S)O[C@@H]%17[C@@H](COP(O)(=S)O[C@@H]%18[C@@H](CO)O[C@H]([C@@H]%18OCCOC)n%18cc(C)c(=O)[nH]c%18=O)O[C@H]([C@@H]%17OCCOC)n%17cc(C)c(N)nc%17=O)O[C@H]([C@@H]%16OCCOC)n%16cnc%17c(N)ncnc%16%17)O[C@H]([C@@H]%15OCCOC)n%15cc(C)c(N)nc%15=O)O[C@H]([C@@H]%14OCCOC)n%14cc(C)c(=O)[nH]c%14=O)O[C@H]([C@@H]%13OCCOC)n%13cc(C)c(=O)[nH]c%13=O)O[C@H]([C@@H]%12OCCOC)n%12cc(C)c(=O)[nH]c%12=O)O[C@H]([C@@H]%11OCCOC)n%11cc(C)c(N)nc%11=O)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c(N)ncnc%10%11)O[C@H]([C@@H]9OCCOC)n9cc(C)c(=O)[nH]c9=O)O[C@H]([C@@H]8OCCOC)n8cnc9c(N)ncnc89)O[C@H]([C@@H]7OCCOC)n7cnc8c(N)ncnc78)O[C@H]([C@@H]6OCCOC)n6cc(C)c(=O)[nH]c6=O)O[C@H]([C@@H]5OCCOC)n5cnc6c5nc(N)[nH]c6=O)O[C@H]([C@@H]4OCCOC)n4cc(C)c(N)nc4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(=O)[nH]c3=O)O[C@H]([C@@H]2OCCOC)n2cnc3c2nc(N)[nH]c3=O)O[C@H]1n1cnc2c1nc(N)[nH]c2=O WWFDJIVIDXJAQR-FFWSQMGZSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 101150031865 ACVR2B gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 238000010167 Fisher's least significant difference multiple comparison test Methods 0.000 description 1
- 102100020921 Follistatin Human genes 0.000 description 1
- 102100036001 G-protein coupled receptor-associated sorting protein 1 Human genes 0.000 description 1
- 101710142641 G-protein coupled receptor-associated sorting protein 1 Proteins 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101000635885 Homo sapiens Myosin light chain 1/3, skeletal muscle isoform Proteins 0.000 description 1
- 101000966872 Homo sapiens Myotubularin-related protein 2 Proteins 0.000 description 1
- 101000625727 Homo sapiens Tubulin beta chain Proteins 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 101001092933 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Phosphatidylinositol-3-phosphatase Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102100030740 Myosin light chain 1/3, skeletal muscle isoform Human genes 0.000 description 1
- 102100040602 Myotubularin-related protein 2 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150032199 Rplp0 gene Proteins 0.000 description 1
- 101150081851 SMN1 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100024717 Tubulin beta chain Human genes 0.000 description 1
- 101710160038 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000054677 human MSTN Human genes 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229950001015 nusinersen Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to methods for determining whether a patient will respond to a myostatin pathway inhibitor, methods for treating muscle atrophy or muscle wasting conditions and methods for monitoring such treatment.
- Myostatin also known as Growth Differentiation Factor-8 (GDF-8), is a member of the transforming growth factor-beta (TGF-beta) family of proteins whose function appears to be conserved across species. Because several spontaneous mutations in the myostatin gene have been correlated with muscle hypertrophy in animals or even in man, myostatin inhibition had been seen as a promising tool to fight muscle atrophy in different diseases including muscle diseases.
- GDF-8 Growth Differentiation Factor-8
- Myostatin is a secreted protein, synthetized by skeletal muscle as a precursor, which undergoes maturation steps.
- myostatin inhibitory drugs have been designed targeting different stages of the myostatin biosynthesis or pathway including (i) monoclonal antibodies targeting myostatin, (ii) monoclonal antibodies targeting myostatin’s receptor, activin type II receptor (ActRII), (iii) ActRII decoys, and (iv) follistatin overexpression, which functions as a myostatin antagonist by preventing receptor binding (for review see Cohen et al., 2015).
- US2011/0166082 describes a method for treating skeletal muscle mass deficiency and proposes a method comprising (i) measuring the circulating levels of myostatin in patients before anti-myostatin injection and (ii) if this level is above a selected threshold level for normal average individuals (typically more than 10-20%) or (iii) if the patient presents obvious muscle wasting, then the patient is a candidate for anti-myostatin administration.
- US2011/0166082 therefore teaches that patients presenting with obvious muscle wasting or with myostatin levels above that of normal average individuals are candidates for an anti-myostatin approach.
- the present inventors have recognised that the poor clinical efficacy of anti-myostatin molecules in several of the human studies to date was due to the surprising fact that the expression level of the targeted protein itself was reduced, and/or the level of ActRII strongly decreased. Indeed, a treatment targeting circulating myostatin is unlikely to work if the level of circulating myostatin is already very low in patients. Similarly, activated myostatin C-peptide cannot transmit its signalling to the muscle fibre if insufficient ActRII is expressed. A combination of both limiting conditions — a further surprising finding — additionally potentiates the refractory state of skeletal muscle to a myostatin inhibition approach.
- the present inventors have analyzed the expression levels of different actors of the myostatin network at mRNA and/or protein levels in the sera and/or biopsies of patients with different muscular diseases and in a mouse model of the congenital myotubular myopathy, and in a dog model of Duchenne muscular dystrophy, all of which have an underlying muscle wasting/atrophying process in common.
- the inventors have determined that in several neuromuscular diseases the myostatin pathway is shut down at mRNA level in muscle biopsies, leading to low levels of circulating and endogenous muscle myostatin and high levels of follistatin.
- This regulation of the myostatin network is disease-dependent, with the patients affected by the most atrophying disease showing the strongest extinction of the myostatin pathway. Importantly, decreased myostatin synthesis is frequently accompanied by down-regulation of the muscle ActRII, thereby further down-regulating the myostatin pathway. Further inhibition of this pathway by an exogenous compound (such as a monoclonal antibody or vector-mediated inhibition) in the presence of strong down regulation in severely affected muscles may not be an efficient strategy to increase muscle mass. However, the inventors have surprisingly found that this blockage is reversible upon proper treatment of the primary cause of the disease, as exemplified with the myotubular myopathy model described later in this specification.
- the present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond
- the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, the patient will respond to treatment with a myostatin and/or activin A pathway inhibitor.
- activin A binds to the ActRII receptor and activates Smad2 ⁇ 3 signalling.
- Activin A is now known to suppress muscle growth in a similar way to myostatin (Latres et al 2017), and indeed, has been described as a more potent regulator of muscle mass in primates than myostatin.
- Activin A levels are indicative of myostatin levels and can therefore provide an indication of whether a subject is likely to respond to an anti-myostatin approach.
- systemic levels of myostatin and/or follistatin, and levels of follistatin, myostatin and/or ActRII as expressed in the muscle may be considered to be essential actors of the myostatin pathway.
- activin A due to its action on the ActRII receptor, activin A can be considered to be an essential actor of the downstream myostatin pathway.
- Systemic levels of myostatin and/or follistatin and/or activin A provide an indication of the overall homeostasis of the skeletal muscle system, and consequently of the disease status of the patient affected by a muscle wasting or atrophying condition.
- an important feature of the present invention is the measurement of levels of myostatin and/or ActRII and/or follistatin and/or activin A in at least one muscle biopsy obtained from a treatment target muscle.
- the present inventors have determined that low circulating levels of myostatin are not necessarily indicative of net muscle loss. Indeed, in muscle atrophy or muscle wasting conditions it appears that the body automatically inhibits the myostatin pathway in order to try to stabilise the affected muscle(s).
- the muscle fibres may be present, but will be in a dormant state, unable to respond to a myostatin pathway inhibitor. However, depending on the specific muscle atrophy or muscle wasting condition, different muscles and/or different parts of particular muscles (i.e. different fascicles) may be affected.
- a key feature of the present invention therefore relates to determining levels of myostatin and/or ActRII and/or follistatin and/or activin A in at least one muscle biopsy obtained from a treatment target muscle. For example, if a medical practitioner is seeking to improve ambulation, key treatment target muscles will be weight-bearing muscles in the lower limbs.
- the determination of a high or low level of myostatin, GDF11, activin A, follistatin or ActRII is based on a control/threshold level, which is typically determined from a relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition by comparing them to a healthy, age- and gender matched control population. These individuals with a muscle wasting or atrophying condition have very low systemic and/or local levels of myostatin and/or ActRII and/or activin A and/or high systemic and/or local levels of follistatin, indicating that the myostatin pathway is suppressed and therefore incapable of responding to a myostatin pathway inhibitor.
- the myostatin and/or ActRII and/or activin A levels of the population of individuals with significant muscle atrophy and/or severe or advanced muscle wasting condition may be 10% to 70% lower, or 20% to 50% lower, or 20% to 30% lower.
- the relevant population can be defined based on, for example, diet, lifestyle, age, ethnic background or any other characteristic that can affect the normal levels of the markers.
- control/threshold levels Once the control/threshold levels are known, the measured levels can be compared and the significance of the difference determined using standard statistical methods. If there is a substantial difference between the measured level and the control/threshold level (i.e. a statistically significant difference), then the individual from whom the levels have been measured may be considered to have unusual levels of the marker, those unusual levels being higher or lower than the control/threshold level determined from the relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition.
- a substantial difference between the measured level and the control/threshold level i.e. a statistically significant difference
- the levels of myostatin and/or ActRII and/or activin A are statistically higher than the threshold level and/or if the levels of follistatin are statistically lower than the threshold level this is an indication that the myostatin pathway of the individual from whom the levels have been measured may be capable of responding to a myostatin and/or activin A pathway inhibitor.
- a patient that is likely to respond to treatment will therefore have a higher level of myostatin and/or ActRII and/or activin A than a control/threshold level determined from a relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition, but will also likely have a lower myostatin and/or ActRII and/or activin A level than a healthy, age- and gender matched control population.
- the method may further comprise administering a myostatin or activin A pathway inhibitor to the patient.
- the patient and/or subject is preferably a mammal, including a human, and may be of any age or a paediatric or a geriatric patient.
- the patient may have or be suspected of having muscle atrophy or a muscle wasting condition.
- the present invention also provides a method for treating muscle atrophy or a muscle wasting condition, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient; and if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, administering a myostatin pathway inhibitor to the patient.
- ActRII activ
- the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, administering a myostatin or activin A pathway inhibitor to the patient.
- the myostatin or activin A pathway inhibitor may be administered systemically or may be administered locally to one or more target muscles, such as skeletal muscles.
- Suitable routes of administration may include parenteral administration, such as intravenous, subcutaneous or intramuscular administration.
- the myostatin or activin A pathway inhibitor may be administered in the form of a pharmaceutical composition, which may be sterile and may comprise one or more pharmaceutically acceptable carriers or excipients. Suitable carriers and excipients will be familiar to the skilled person and may be optimised in line with the intended route of delivery.
- suitable pharmaceutical compositions may include buffers, binders, preservatives, thickeners or antioxidants.
- Myostatin, follistatin, activin A, GDF11, and/or ActRII may be measured as protein or mRNA.
- Proteins and mRNA may be measured using methods that will be familiar to the person skilled in the art. For example, proteins may be identified by contacting the protein of interest with an appropriate antibody, which may comprise a label. Assay techniques such as ELISA or Western blot may be used.
- mRNA may be measured by techniques such as PCR, including qPCR or digital PCR, utilising primers specific to the target mRNA sequence of interest.
- the present invention relates to evaluation of systemic GDF11 levels in patients having or suspected of having in spinal muscular atrophy (SMA).
- the systemic sample may be measured from a serum sample obtained from the patient.
- GDF11 is a known negative regulator of myogenesis (Gamer et al 2001).
- AAV-mediated gene delivery has been shown to inhibit skeletal muscle growth (Jin et al 2018) and supraphysiological administration of GDF11 has been shown to induce cachexia (Jones et al 2018).
- GDF11 is also known to act via the ActII receptor and thereby induce muscular atrophy, selective blockage of GDF11 in SMA may provide a useful approach to alleviate muscle atrophy in this condition.
- myostatin is synthesised by muscle fibres as an inactive precursor or pro-peptide, which is a 375 amino acid protein.
- the pro-peptide is proteolytically processed into a shorter, mature, active form by a protease, which cleaves the covalently bound NH2-terminal, or “pro-domain” portion of the protein, resulting in an active COOH-terminal dimer.
- the myostatin pro-peptide has two distinct functions in guiding protein folding and regulating biological activity of myostatin (through cleavage of the pro-domain).
- the mature form of the myostatin protein consists of two identical 109 amino acid residues.
- myostatin binds to the ActII receptor to activate a downstream cell signalling cascade via Alk-3 or Alk-4, the signalling cascade including activation of transcription factors such as SMAD2 and SMAD3, which induce myostatin-specific gene expression.
- myostatin may be measured in the pro-peptide form, i.e. as a latent complex (non-covalently bound to its pro-domain) or bound to other inhibitory proteins, such as follistatin.
- myostatin is measured in the mature protein form.
- Muscle biopsies will be familiar to the person skilled in the art and may be obtained from any target muscle.
- the muscle biopsy is obtained from a skeletal muscle.
- the skeletal muscle is preferably the treatment target muscle of interest.
- Suitable systemic samples include bodily fluid samples, such as a whole blood sample, a serum sample, a plasma sample or a urine sample.
- the muscle atrophy or muscle wasting condition may be selected from a muscle dystrophy such as: Becker Muscular Dystrophy (BMD), Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Dystrophy (FSHD), Limb Girdle Muscular Dystrophy (LGMD), or Congenital Muscular Dystrophy (CMD); a central or spinal muscular atrophy such as: Amyotrophic Lateral Sclerosis (ALS) or Spinal Muscular Atrophy (SMA); a neurogenic muscular atrophy such as: Charcot-Marie-Tooth peripheral neuropathy; a congenital myopathy such as: Myotubular myopathy; an ‘idiopathic’ muscle wasting condition such as: Inclusion Body Myositis (IBM) or age-related sarcopenia.
- BMD Becker Muscular Dystrophy
- DMD Duchenne Muscular Dystrophy
- FSHD Facioscapulohumeral Dystrophy
- LGMD Limb Girdle Muscular Dy
- the myostatin pathway inhibitor may be a myostatin antagonist or an ActRII antagonist.
- the myostatin pathway inhibitor may be a myostatin inhibitor.
- Suitable myostatin antagonists include anti-myostatin antibodies, myostatin decoys, follistatin, or follistatin analogues.
- Myostatin pathway inhibitors may also include abolishing or impeding the myostatin pathway through the use of siRNA, shRNA, antisense oligonucleotides, miRNA interference through gene silencing using exon skipping or nuclease-mediated invalidation through CRISPR or TALEN.
- the myostatin antagonist may be provided in the form of myostatin pro-peptide overexpression or altered myostatin pro-peptide expression, either or both of which may be delivered by gene therapy. Altered myostatin pro-peptide expression may comprise tighter binding of the pro-domain to the mature myostatin protein, thereby inhibiting cleavage of the pro-peptide into mature myostatin, and thereby inhibiting myostatin function.
- Suitable ActRII antagonists include anti-ActRII antibodies, ActRII decoys or inhibitors of effectors downstream of the ActRII, as well as small molecules down-regulating myostatin.
- soluble ActRII may be administered to outcompete the receptor, acting as a decoy for the mature myostatin protein.
- the myostatin pathway inhibitor may be selected from one or more molecules known to block myostatin pathways including but not limited to PF06252616, FS344, Bimagrumab, ACE-083, ACE-031, ACE-2494, AAV1-FS344, AAV9-FS344, BMS-986089 or MYO-029.
- GDF11 pathway inhibition may be achieved through anti-GDF11 antibodies or human IgG1 Fc-fused GDF11 propeptide.
- the present invention provides a dystrophin or myotubularin (MTM1) gene or pathology correcting therapy and a myostatin pathway inhibitor for use in treating muscle atrophy or a muscle wasting condition.
- MTM1 myotubularin
- muscle atrophy or a muscle wasting condition will lead to muscle fibres becoming dormant, rendering them unable to respond to a myostatin pathway inhibitor.
- the present inventors have found that this effect of muscle atrophy or a muscle wasting condition can be reversed utilising gene therapy or pathology correcting therapy.
- MTM1 encodes a phosphatidylinositol-3-phosphatase and is required for muscle cell differentiation.
- reinstating MTM1 gene expression leads to reactivation of myostatin synthesis by muscle fibres. The muscle is then able to respond to a myostatin pathway inhibitor and improvements in myogenesis, i.e.
- Dystrophin deficiency underlies the pathology of Duchenne and Becker muscular dystrophies and reinstating dystrophin gene expression can lead to reactivation of myostatin synthesis by muscle fibres, rendering them able to respond to a myostatin pathway inhibitor.
- the muscle atrophy or a muscle wasting condition may be any genetically determined neuromuscular condition where a gene therapy, a cell therapy, or a small molecule therapy is capable of stopping or reverting the underlying pathogenic mechanism. All genetic muscle disorders listed above may be suitable for treatment.
- Suitable myostatin pathway inhibitors and forms and routes of administration include those described above in relation to other aspects of the invention.
- a pathology correcting therapy may include a cell or small molecule therapy capable of stopping or reversing the pathology underlying the muscle atrophy or muscle wasting condition.
- a small molecule therapy may be used to provide an indirect gene therapy, acting by targeted promotor stimulation or splicing modification.
- Gene therapy may be provided in the form of a recombinant viral vector supplying or partially or fully correcting a missing gene such as MTM1 or the dystrophin gene, or suppressing a damaging gene expression such as SOD-1 through RNA interference or out-of-frame exon skipping of the damaging gene.
- Suitable viral vectors will be familiar to the skilled person and include a retrovirus, an adenovirus, a lentivirus, herpes simplex virus, and adeno-associated virus. Other viral vectors are envisaged.
- the gene or pathology correcting therapy and myostatin pathway inhibitor may be administered separately, simultaneously or sequentially.
- the gene or pathology correcting therapy is administered prior to the myostatin pathway inhibitor.
- the gene or pathology correcting therapy may be administered at least two weeks, or at least three weeks, or at least four weeks prior to the myostatin pathway inhibitor.
- the gene or pathology correcting therapy may be administered at least one month or at least two months or at least three months prior to the myostatin pathway inhibitor. The time period will be dependent on the underlying pathology and can be determined by a medical practitioner.
- the myostatin pathway inhibitor can be administered. Muscle biopsies and/or systemic samples as described above may be utilised to monitor levels of essential actors of the myostatin pathway in the target muscle(s).
- the present invention also provides a method for improving or monitoring dystrophin or MTM1 gene or pathology correcting therapy, the method comprising determining a level of myostatin and/or ActRII and/or follistatin in a sample obtained from a subject.
- the level of myostatin and/or follistatin is compared to a threshold as described above.
- a threshold as described above.
- at least one further round of gene or pathology correcting therapy may be administered.
- the present invention provides a dystrophin or MTM1 gene or pathology correcting therapy for use in treating muscle atrophy or a muscle wasting condition in a subject, wherein the subject is characterised by having a myostatin and/or ActRII level lower than a threshold level.
- the subject may be characterised by having a systemic or local level of myostatin or ActRII that is lower than a threshold level. Threshold levels can be determined as described above. Suitable samples may be obtained and/or measured as described in relation to the aspects of the invention.
- the subject may be characterised by having at least one skeletal muscle that does not express ActRII at normal levels, said muscle being determined by at least one muscle biopsy indicating reduced levels of active ActRII.
- the present invention also provides a method for determining anabolic capacity of the skeletal muscle system of a subject, the method comprising: (a) determining a level of myostatin and/or follistatin in a systemic sample obtained from the subject; and/or (b) determining a level of myostatin and/or ActRII and/or follistatin in at least one skeletal muscle biopsy obtained from the subject; wherein if (i) the level of myostatin in the systemic sample is lower than a threshold and/or if the level of follistatin in the sample is higher than a threshold; and/or (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is lower than a threshold level and/or if the level of follistatin in the at least one biopsy sample is higher than a threshold level, the anabolic capacity of the skeletal muscle system is compromised, indicating the existence of a muscle wasting process in the subject. Threshold levels can be determined
- Myostatin deficiency results in muscle hypertrophy and shifts muscle from aerobic toward anaerobic energy metabolism, resulting in reduced mitochondrial respiration, reduced expression of peroxisome proliferator-activated receptor (PPAR) transcriptional regulators, increased endonuclease activity and exercise induced lactic acidosis. This results in diminished exercise capacity and increased fatigability.
- PPAR peroxisome proliferator-activated receptor
- This effect is exclusively regulated through myostatin signalling via ActRII.
- the essential effectors of the myostatin pathway are therefore biomarkers of the anabolic homeostatic state of the muscular tissue and can be used for pre-symptomatic monitoring of muscle atrophy or muscle wasting conditions, and/or for monitoring the effects of therapy on such conditions.
- the method for determining anabolic capacity of the skeletal muscle system of a subject may further comprise comparing one or more of the levels of myostatin, ActRII receptor and/or follistatin to thresholds to determine the activity of the muscle wasting process.
- the subject may be treated with a dystrophin or MTM1 gene or pathology correcting therapy and/or a myostatin pathway inhibitor.
- the present invention also provides a method for determining inclusion of subjects into a clinical trial for evaluation of a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or ActRII and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, admitting the subject to the clinical trial.
- the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, the patient is admitted into the clinical trial.
- Myostatin and activin A are both biomarkers of muscle health and atrophy.
- Activin A levels are indicative of myostatin levels and can therefore provide an indication of whether a subject is likely to respond to an anti-myostatin approach.
- myostatin levels are indicative of activin A levels and can therefore provide an indication of whether a subject is likely to respond to an anti-activin A approach.
- the method for determining inclusion of subjects into a clinical trial for evaluation of a myostatin pathway inhibitor may further comprise commencing the clinical trial and administering the myostatin pathway inhibitor or a placebo control to the subject.
- the present invention additionally provides a method for determining whether a patient having or suspected of having spinal muscular atrophy (SMA) will respond to treatment, the method comprising: determining a level of myostatin and/or follistatin and/or Growth differentiation factor 11 (GDF11) in a systemic sample obtained from the patient; wherein a level of GDF11 above a threshold is associated with SMA; and wherein if the level of myostatin is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold, the patient will respond to treatment.
- SMA spinal muscular atrophy
- SMA Spinal muscular atrophy
- SMA Spinal muscular atrophy manifests in various degrees of severity, which all have in common progressive muscle wasting and mobility impairment. Proximal muscles and respiratory muscles are affected first. Other body systems may be affected as well, particularly in early-onset forms of the disorder. SMA is the most common genetic cause of infant death. Due to the severity of its effects (which may affect the respiratory muscles) and the age of patients (who are commonly in infancy), it is often not possible to obtain a muscle biopsy sample, especially if a general anaesthetic would be required. However, the present inventors have determined that there is an association between abnormally high levels of systemic GDF11 and SMA. This may be an indication that GDF11 can be used in combination with other systemic markers of the myostatin pathway to determine whether a patient will be suitable for therapy to treat SMA.
- GDF11 also known as bone morphogenetic protein 11 (BMP-11), is a myostatin(GDF8)-homologous protein that acts as an inhibitor of nerve tissue growth. Like myostatin, GDF11 binds to the ActII receptor. GDF11 has been shown to suppress neurogenesis through a pathway similar to that of myostatin, including stopping the progenitor cell-cycle during G-phase. The similarities between GDF11 and myostatin imply that similar signalling pathways are used to control tissue growth during both muscular and neural development.
- suitable systemic samples for use in methods of the present invention include bodily fluid samples, such as a whole blood sample, a serum sample, a plasma sample or a urine sample.
- the systemic sample is a serum sample.
- the method may further comprise administering a treatment for SMA, such as Nusinersen, to a patient determined to respond to the treatment.
- a treatment for SMA such as Nusinersen
- the method may comprise determining levels of GDF11 in a subject with spinal muscular atrophy and, if levels are above a threshold of above 50-100% of normal, treating such a subject with a GDF11 inhibitor.
- the patient and/or subject is preferably a mammal, including a human, and may be of any age or a paediatric or a geriatric patient.
- the patient may be an infant.
- the patient may have or be suspected of having SMA.
- FIGS. 3 A- 3 I Myostatin network in Mtm1-KO mice.
- the tibialis anterior (TAs) of 3 week-old Mtm1-KO mice were injected with either PBS (A, F, G, H, I), an AAV vector coding the myostatin pro-peptide D76A mutant (PropD76A) (A), an AAV vector coding Mtm1 (Mtm1) (F, G, H, I), or an AAV coding both Mtm1 and propD76A (F, G, H, I).
- PBS A, F, G, H, I
- An AAV vector coding the myostatin pro-peptide D76A mutant PropD76A
- Mtm1 Mtm1
- Mtm1 and propD76A F, G, H, I
- the weights (B), Msnt mRNA (C), Fsnt mRNA (D) or ActRIIb mRNA (E) were measured at 14, 21 or 30 days in the TAs of either Mtm1-KO mice (KO) or wild type littermates (WT).
- FIG. 4 A Natural history of circulating myostatin levels in healthy and Golden Retriever muscular dystrophy (GRMD) dogs. While the myostatin level increases in healthy dogs as they age, it decreases in GRMD dogs. At the age of 2.5 months the myostatin level is sufficient to distinguish heathy and GRMD dogs.
- FIG. 4 B Locoregional injection of an AAV vector coding a dog microdystrophin. The injections restrict the myostatin decrease observed in GRMD dogs.
- FIGS. 4 C and 4 D The systemic injection of a low or high dose of an AAV vector coding a dog microdystrophin is not sufficient to increase myostatin levels in GRMD dogs.
- FIG. 5 The different elements of FIGS. 4 are combined. A difference in circulating myostatin levels is observed in the low dose, high dose and untreated groups. The more microdystrophin is expressed, the higher the myostatin levels are.
- mice were handled according to French and European legislation on animal care and experimentation, and protocols were approved by the institutional ethical committee.
- the constitutive knockout of the myotubularin gene (Mtm1-KO, also named BS53d4-129pas) was described previously (Buj-Bello et al, 2002). Wild-type littermate males were used as controls.
- a recombinant serotype 1 AAV vector containing mutated myostatin propeptide D76A under the CMV promoter was produced as previously described (Bartoli et al, 2007).
- Mouse Mtm1 cDNA (AF073996, NCBI) was cloned in the AAV expression pGG2-DES plasmid, which contains the human desmin promoter.
- Recombinant serotype 1 viral particles (AAV1-Mtm1) were obtained by a tri-transfection procedure from HEK293 cells as previously described (Buj-Bello et al, 2008). Vector titers were expressed as viral genomes per ml (vg/ml).
- AAV vectors were intramuscularly delivered to 3 week-old KO mice and age matched wild type males. Mice were anesthetized by intraperitoneal injection of 5 ⁇ L/body gram of ketamine (20 mg/mL, Virbac) and xylazine (0.4%, Rompun, Bayer). Tibialis anterior (TA) muscles were injected with 3.5 ⁇ 109 vg of AAV-CMV- PropD76A, 5 ⁇ 109 vg of AAV-Mtm1 or sterile phosphate buffer saline (PBS) solution. Muscles were dissected 14 days after injection and frozen in either liquid nitrogen-cooled isopentane or liquid nitrogen for histological and molecular assays.
- Peripheral venous blood was collected from healthy and patients’ volunteers using serum separator tubes (10 mL). After 30 minutes on the benchcoat at room temperature, the tubes were centrifuged at 2000 rpm for 10 min at 4° C. The collected serum (5 mL) was aliquoted and stored at -80° C. until further use.
- the concentrations of either GDF8, FOLLISTATIN, GDF11 or ACTIVIN A in the sera were measured using an ELISA kit (respectively # DGDF8, # DFN00, # DY1958 and # DAC00B R&D Systems Europe, Ltd, Abingdon, United Kingdom) according to the manufacturer’s instructions.
- the optical density was measured using a microplate reader (Infinite 200 Pro, Tecan Group Ltd., Gurnnedorf, Switzerland). Importantly, the myostatin immunoassay was designed to recognize mature GDF8. According to the manufacturer, no significant cross-reactivity or interference was observed in the presence of 50 ng/ml (20 times more than the highest value measured in our experiment) of different proteins including the GDF8 propeptide, GDF11 or GDF15. We have experimentally confirmed this result by using 4000 pg/ml of recombinant GDF11. The absence of cross reactivity with FOLLISTATIN (8000 pg/ml), ACTIVIN 1 (4000 pg/ml) and GASP-1 (4000 pg/ml) was also experimentally validated.
- RNA samples were transferred in tube containing 1.4 mm ceramic beads (Precellys, Bertin Corp, Maryland, United State) plus 1 mL of Trizol (Life technologies, Saint Aubin, France) and shaken 3 times at 5700 rpm for 30 s. Between each cycle, tubes were incubated in ice during at least 1 min. Total RNAs were extracted using trizol according to the manufacturer’s protocol (Life technologies, Saint Aubin, France). The quantity of RNA was determined using a nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The reverse transcription and polymerase chain reaction (PCR) were described previously 29.
- PCR polymerase chain reaction
- qPCRs were performed on a LightCycler 480 Real-Time PCR System (Roche, Meylan, France) in a final volume of 4 ⁇ l with 0.4 ⁇ l of reverse transcriptase (RT) product, 0.18 ⁇ l each of forward and reverse primers (20 pmol/ml) and 4.5 ⁇ l of SYBRGreen Mastermix (Roche, Basel, Switzerland). After qPCR, the PCR products were run on a 2% agarose gel and were cloned using the Topocloning kit (Life Technologies, Saint Aubin, France) and sequenced. Primers used in this study are described in Table 3.
- Quantitative PCR was designed according to the MIQE standards 30. Among the 87 items to review, 57 were classified as essential. All were followed. In particular, to determine the best human housekeeping gene, 5 genes were evaluated: B2M, GAPDH, GUS, PO and PPIA. A MANOVA test has demonstrated that none of these genes were suitable for housekeeping since significant statistical changes were observed between the different groups. GUS, PO and PPIA were then chosen to calculate the expression normalization factor for each sample using geNorm software (V3.5). To determine the best housekeeping mouse gene, 6 genes were evaluated: Gapdh, Po, Hprt1, ⁇ -actin, ⁇ -tubulin and 18S and Po was chosen.
- Serum concentrations of MSTN, FSTN, GDF11 and ACTIVIN A were determined in patients with different pathologies affecting skeletal muscles (summarized in Table 1).
- BMD Becker Muscular Dystrophy
- DMD Duchenne Muscular Dystrophy
- SMA Spinal Muscular Atrophy
- IBM International-Body Myositis
- FSHD Facioscapulohumeral Dystrophy
- MG Myasthenia Gravis
- GDF11 No modification of GDF11 was noted, except in SMA sera in which a massive overexpression was observed.
- SMA 135.6% ⁇ 71.3 and DMD 189.4% ⁇ 35.2 compared to controls respectively FIG. 1 B .
- BMD, IBM and FSHD patients who clinically show a less pronounced muscle atrophy, have more circulating myostatin than DMD and SMA patients but less than controls (BMD 71% ⁇ 23.7, IBM 71% ⁇ 55.6 and FSHD 66% ⁇ 35 compared to controls respectively).
- the levels of circulating FSTN were not increased in BMD patients (85.5 % ⁇ 22.4) whereas a trend to an increase was observed in both IBM and FSHD patients (146.3 ⁇ 70.9 and 145.8 ⁇ 72.8).
- MG patients who do not show any atrophy, no modification of MSTN nor FSTN was observed.
- the MSTN pathway is down-regulated at mRNA level in the most atrophying diseases
- MSTN is mainly produced by skeletal muscle
- the mRNA expression levels of several genes implicated in the myostatin pathway were investigated in muscle biopsies (summarized in Table 2).
- SMA biopsy could not be studied since the diagnosis is essentially genetic and a muscle biopsy is not normally performed in SMA.
- a massive down-regulation of MSTN was observed in both the DMD and IBM patients as only 29% and 12% of the respective mRNA levels were detectable ( FIG. 2 A ).
- XLMTM X-linked myotubular myopathy
- Mtm1-KO mice Because at 3 weeks, Mtm1-KO mice already show an important loss of muscle weight compared to WT littermates (84% ⁇ 12% of residual mRNA at 14 days, 50% ⁇ 8.1% at 21 days and 34.5% ⁇ 7.2% at 30 days in tibialis anterior, FIG. 3 B ), the expression level of the myostatin network was investigated.
- a strong down expression of Mstn (47.6% ⁇ 18.6% of residual mRNA at 14 days, 22.5% ⁇ 7.8% at 21 days and 25% ⁇ 6.5% at 30 days, FIG. 3 C ), associated with a massive up-regulation of Fstn (159% ⁇ 44.9% of residual mRNA at 14 days, 567% ⁇ 201% at day 21 and 768% ⁇ 190% at day 30, FIG.
- the tibialis anterior of WT or Mtm1-KO mice were next intramuscularly injected with either an AAV coding the Mtm1 gene (AAV-Mtm1) or a combination of the AAV-Mtm1 gene and the AAV16 PropD76A.
- AAV-Mtm1 AAV coding the Mtm1 gene
- muscle histology was greatly improved with an increase of cross-sectional fiber size, and an improved intracellular architecture revealed after NADH-TR staining (data not shown).
- the abnormal localizations of the dihydropyrine 1 ⁇ receptor (DHPR1 ⁇ ) and ryanodine receptor 1 (RYR1) were partially restored.
- mice and humans could explain the apparent contradictory results in mice and humans regarding the efficacies of anti-myostatin approaches. Indeed, the outcome of a clinical trial in DMD patients was not encouraging, while myostatin pathway blockade has been successful in mdx mice. Despite the fact that Duchenne patients and mdx mice share a mutation in the same gene, no important muscle atrophy is observed before 6 months of age in the mdx mouse and experiments are usually performed before this age. Moreover, even if myostatin levels are lower in mdx mouse than in wild type mouse, the endogenous circulating myostatin level is at least 50 times higher in mice than in humans. This could be one of the reasons why anti-myostatin approaches in the mdx model were successful.
- Golden Retriever muscular dystrophy (GRMD) dog samples were obtained from either the Boisbonne center for gene therapy or the lich Nationale Veterinaire d′Alfort. Some dogs have been locoregionaly (single administration of 1 ⁇ 10 13 vg/kg via transvenous perfusion of one forelimb) or systemically (single dose of 1 ⁇ 10 14 vg/kg or 1 ⁇ 10 13 vg/kg) treated with a rAAV2/8 vector encoding a canine microdystrophin, as described in Le Guiner et al (Nat Comms, 2017).
- Injected dogs were monitored for several months and blood samples were collected at different time before the dogs were euthanized.
- GDF8 concentrations of GDF8 were assessed by ELISA (#DGDF80, R&D Systems Europe, Ltd, Abingdon, United Kingdom) according to the manufacturer’s instructions.
- the optical density was measured using a microplate reader (Infinite 200 Pro, Tecan Group Ltd., Gurnnedorf, Switzerland).
- Results can be seen in FIGS. 4 and 5 and demonstrate that muscle wastage can be stabilised by gene therapy with a rAAV2/8 vector encoding a canine microdystrophin, particularly when the therapy is administered systemically at the high dose ( FIG. 4 D ).
- AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis, Human molecular genetics (2008).17 (14), 2132.
Abstract
Description
- This is a continuation of U.S. Pat. Application No. 16/492,590, filed on Sep. 9, 2019, incorporated herein by reference, which is a § 371 U.S. national stage of International Application No. PCT/GB2018/050619, filed Mar. 12, 2018, and which claims the benefit of Great Britain Patent Application No. 1713597.1, filed on Aug. 24, 2017 and Great Britain Patent Application No. 1703869.6, filed on Mar. 10, 2017.
- The contents of the electronic sequence listing (8050-103241-02_Sequence_Listing.xml; having a file size of 53,399 bytes; Date of Creation: May 5, 2023) is herein incorporated by reference in its entirety.
- The present invention relates to methods for determining whether a patient will respond to a myostatin pathway inhibitor, methods for treating muscle atrophy or muscle wasting conditions and methods for monitoring such treatment.
- Skeletal muscle mass is controlled by different pathways among them the myostatin pathway. Myostatin, also known as Growth Differentiation Factor-8 (GDF-8), is a member of the transforming growth factor-beta (TGF-beta) family of proteins whose function appears to be conserved across species. Because several spontaneous mutations in the myostatin gene have been correlated with muscle hypertrophy in animals or even in man, myostatin inhibition had been seen as a promising tool to fight muscle atrophy in different diseases including muscle diseases.
- Myostatin is a secreted protein, synthetized by skeletal muscle as a precursor, which undergoes maturation steps. Several myostatin inhibitory drugs have been designed targeting different stages of the myostatin biosynthesis or pathway including (i) monoclonal antibodies targeting myostatin, (ii) monoclonal antibodies targeting myostatin’s receptor, activin type II receptor (ActRII), (iii) ActRII decoys, and (iv) follistatin overexpression, which functions as a myostatin antagonist by preventing receptor binding (for review see Cohen et al., 2015). During the last 15 years, at least 6 molecules (MYO-029, BMS-986089, PF-14 06252616, ACE-083/-031, BYM338, FS-344) have been developed by pharmaceutical companies to block myostatin pathways (https://clinicaltrials.gov). These molecules are/were evaluated in several neuromuscular diseases that show muscular wasting or atrophy but so far the published results have been largely disappointing. Significant improvements in muscle strength or physical function have not been reached, with the exception of one
phase 2 trial using an AAV vector encoding the follistatin isoform FS344 intramuscularly injected in Becker Muscular Dystrophy (BMD) patients. Several explanations have been proposed, among them the specificity of the drugs themselves and the possibility that they do not target the correct form of myostatin or do not target other growth factors besides myostatin implicated in muscle mass regulation. However, in animals, several laboratories have demonstrated that myostatin pathway inhibition leads to muscle hypertrophy and enhances tetanic force in controls or in several murine models of muscle diseases such as the mdx mouse, a murine model for Duchenne Muscular Dystrophy (DMD). - Some attempts have been made to improve the clinical efficacy of anti-myostatin treatment. For example, US2011/0166082 describes a method for treating skeletal muscle mass deficiency and proposes a method comprising (i) measuring the circulating levels of myostatin in patients before anti-myostatin injection and (ii) if this level is above a selected threshold level for normal average individuals (typically more than 10-20%) or (iii) if the patient presents obvious muscle wasting, then the patient is a candidate for anti-myostatin administration. US2011/0166082 therefore teaches that patients presenting with obvious muscle wasting or with myostatin levels above that of normal average individuals are candidates for an anti-myostatin approach.
- The present inventors have recognised that the poor clinical efficacy of anti-myostatin molecules in several of the human studies to date was due to the surprising fact that the expression level of the targeted protein itself was reduced, and/or the level of ActRII strongly decreased. Indeed, a treatment targeting circulating myostatin is unlikely to work if the level of circulating myostatin is already very low in patients. Similarly, activated myostatin C-peptide cannot transmit its signalling to the muscle fibre if insufficient ActRII is expressed. A combination of both limiting conditions — a further surprising finding — additionally potentiates the refractory state of skeletal muscle to a myostatin inhibition approach. The present inventors have analyzed the expression levels of different actors of the myostatin network at mRNA and/or protein levels in the sera and/or biopsies of patients with different muscular diseases and in a mouse model of the congenital myotubular myopathy, and in a dog model of Duchenne muscular dystrophy, all of which have an underlying muscle wasting/atrophying process in common. The inventors have determined that in several neuromuscular diseases the myostatin pathway is shut down at mRNA level in muscle biopsies, leading to low levels of circulating and endogenous muscle myostatin and high levels of follistatin. This regulation of the myostatin network is disease-dependent, with the patients affected by the most atrophying disease showing the strongest extinction of the myostatin pathway. Importantly, decreased myostatin synthesis is frequently accompanied by down-regulation of the muscle ActRII, thereby further down-regulating the myostatin pathway. Further inhibition of this pathway by an exogenous compound (such as a monoclonal antibody or vector-mediated inhibition) in the presence of strong down regulation in severely affected muscles may not be an efficient strategy to increase muscle mass. However, the inventors have surprisingly found that this blockage is reversible upon proper treatment of the primary cause of the disease, as exemplified with the myotubular myopathy model described later in this specification.
- Accordingly, in a first aspect the present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.
- Additionally or alternatively, the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, the patient will respond to treatment with a myostatin and/or activin A pathway inhibitor. Like myostatin, activin A binds to the ActRII receptor and activates Smad⅔ signalling. Activin A is now known to suppress muscle growth in a similar way to myostatin (Latres et al 2017), and indeed, has been described as a more potent regulator of muscle mass in primates than myostatin. Activin A levels are indicative of myostatin levels and can therefore provide an indication of whether a subject is likely to respond to an anti-myostatin approach.
- In the context of the present invention, systemic levels of myostatin and/or follistatin, and levels of follistatin, myostatin and/or ActRII as expressed in the muscle may be considered to be essential actors of the myostatin pathway. In the context of the present invention, due to its action on the ActRII receptor, activin A can be considered to be an essential actor of the downstream myostatin pathway. Systemic levels of myostatin and/or follistatin and/or activin A provide an indication of the overall homeostasis of the skeletal muscle system, and consequently of the disease status of the patient affected by a muscle wasting or atrophying condition. If levels of circulating myostatin and/or activin A are too low and/or if levels of circulating follistatin are too high this may be an indication that a patient will not respond to treatment with a myostatin pathway inhibitor. However, an important feature of the present invention is the measurement of levels of myostatin and/or ActRII and/or follistatin and/or activin A in at least one muscle biopsy obtained from a treatment target muscle. The present inventors have determined that low circulating levels of myostatin are not necessarily indicative of net muscle loss. Indeed, in muscle atrophy or muscle wasting conditions it appears that the body automatically inhibits the myostatin pathway in order to try to stabilise the affected muscle(s). The muscle fibres may be present, but will be in a dormant state, unable to respond to a myostatin pathway inhibitor. However, depending on the specific muscle atrophy or muscle wasting condition, different muscles and/or different parts of particular muscles (i.e. different fascicles) may be affected. A key feature of the present invention therefore relates to determining levels of myostatin and/or ActRII and/or follistatin and/or activin A in at least one muscle biopsy obtained from a treatment target muscle. For example, if a medical practitioner is seeking to improve ambulation, key treatment target muscles will be weight-bearing muscles in the lower limbs. It is necessary to determine whether those specific muscle groups targeted by an anti-myostatin treatment approach are capable of responding to a myostatin pathway inhibitor, and merely measuring systemic levels of myostatin, activin A or follistatin would not be sufficient to make this determination. In summary: when treating neuromuscular patients, i.e., patients with muscle wasting, measuring both target tissue and serum myostatin gives a surprising result because, as myostatin is synthesized by muscle, it would have been expected that a decrease in circulating myostatin is a reflexion of the muscle wastage. However, the present inventors have demonstrated that this hypothesis is wrong, and a lower synthesis of myostatin was observed at mRNA level in the muscle biopsies.
- The determination of a high or low level of myostatin, GDF11, activin A, follistatin or ActRII is based on a control/threshold level, which is typically determined from a relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition by comparing them to a healthy, age- and gender matched control population. These individuals with a muscle wasting or atrophying condition have very low systemic and/or local levels of myostatin and/or ActRII and/or activin A and/or high systemic and/or local levels of follistatin, indicating that the myostatin pathway is suppressed and therefore incapable of responding to a myostatin pathway inhibitor. For example, when compared to an aged matched population without significant medical disorders the myostatin and/or ActRII and/or activin A levels of the population of individuals with significant muscle atrophy and/or severe or advanced muscle wasting condition may be 10% to 70% lower, or 20% to 50% lower, or 20% to 30% lower. The relevant population can be defined based on, for example, diet, lifestyle, age, ethnic background or any other characteristic that can affect the normal levels of the markers.
- Once the control/threshold levels are known, the measured levels can be compared and the significance of the difference determined using standard statistical methods. If there is a substantial difference between the measured level and the control/threshold level (i.e. a statistically significant difference), then the individual from whom the levels have been measured may be considered to have unusual levels of the marker, those unusual levels being higher or lower than the control/threshold level determined from the relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition. If the levels of myostatin and/or ActRII and/or activin A are statistically higher than the threshold level and/or if the levels of follistatin are statistically lower than the threshold level this is an indication that the myostatin pathway of the individual from whom the levels have been measured may be capable of responding to a myostatin and/or activin A pathway inhibitor.
- A patient that is likely to respond to treatment will therefore have a higher level of myostatin and/or ActRII and/or activin A than a control/threshold level determined from a relevant population of individuals with significant muscle atrophy and/or a severe or advanced muscle wasting condition, but will also likely have a lower myostatin and/or ActRII and/or activin A level than a healthy, age- and gender matched control population.
- Once a patient has been determined to have the capability to respond to treatment with a myostatin pathway inhibitor, the method may further comprise administering a myostatin or activin A pathway inhibitor to the patient.
- The patient and/or subject is preferably a mammal, including a human, and may be of any age or a paediatric or a geriatric patient. In embodiments of the invention the patient may have or be suspected of having muscle atrophy or a muscle wasting condition.
- The present invention also provides a method for treating muscle atrophy or a muscle wasting condition, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient; and if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, administering a myostatin pathway inhibitor to the patient.
- Additionally or alternatively, the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, administering a myostatin or activin A pathway inhibitor to the patient.
- According to the methods of the present invention, the myostatin or activin A pathway inhibitor may be administered systemically or may be administered locally to one or more target muscles, such as skeletal muscles. Suitable routes of administration may include parenteral administration, such as intravenous, subcutaneous or intramuscular administration.
- The myostatin or activin A pathway inhibitor may be administered in the form of a pharmaceutical composition, which may be sterile and may comprise one or more pharmaceutically acceptable carriers or excipients. Suitable carriers and excipients will be familiar to the skilled person and may be optimised in line with the intended route of delivery. For example, suitable pharmaceutical compositions may include buffers, binders, preservatives, thickeners or antioxidants.
- Myostatin, follistatin, activin A, GDF11, and/or ActRII may be measured as protein or mRNA. Proteins and mRNA may be measured using methods that will be familiar to the person skilled in the art. For example, proteins may be identified by contacting the protein of interest with an appropriate antibody, which may comprise a label. Assay techniques such as ELISA or Western blot may be used. mRNA may be measured by techniques such as PCR, including qPCR or digital PCR, utilising primers specific to the target mRNA sequence of interest.
- In an alternative embodiment, the present invention relates to evaluation of systemic GDF11 levels in patients having or suspected of having in spinal muscular atrophy (SMA). The systemic sample may be measured from a serum sample obtained from the patient. GDF11 is a known negative regulator of myogenesis (Gamer et al 2001). AAV-mediated gene delivery has been shown to inhibit skeletal muscle growth (Jin et al 2018) and supraphysiological administration of GDF11 has been shown to induce cachexia (Jones et al 2018). Because GDF11 is also known to act via the ActII receptor and thereby induce muscular atrophy, selective blockage of GDF11 in SMA may provide a useful approach to alleviate muscle atrophy in this condition.
- As mentioned above, myostatin is synthesised by muscle fibres as an inactive precursor or pro-peptide, which is a 375 amino acid protein. The pro-peptide is proteolytically processed into a shorter, mature, active form by a protease, which cleaves the covalently bound NH2-terminal, or “pro-domain” portion of the protein, resulting in an active COOH-terminal dimer. The myostatin pro-peptide has two distinct functions in guiding protein folding and regulating biological activity of myostatin (through cleavage of the pro-domain). The mature form of the myostatin protein consists of two identical 109 amino acid residues. The mature form of myostatin binds to the ActII receptor to activate a downstream cell signalling cascade via Alk-3 or Alk-4, the signalling cascade including activation of transcription factors such as SMAD2 and SMAD3, which induce myostatin-specific gene expression. In embodiments of the invention myostatin may be measured in the pro-peptide form, i.e. as a latent complex (non-covalently bound to its pro-domain) or bound to other inhibitory proteins, such as follistatin. Preferably myostatin is measured in the mature protein form.
- Muscle biopsies will be familiar to the person skilled in the art and may be obtained from any target muscle. In preferred embodiments of the invention the muscle biopsy is obtained from a skeletal muscle. The skeletal muscle is preferably the treatment target muscle of interest.
- Suitable systemic samples include bodily fluid samples, such as a whole blood sample, a serum sample, a plasma sample or a urine sample.
- The muscle atrophy or muscle wasting condition may be selected from a muscle dystrophy such as: Becker Muscular Dystrophy (BMD), Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Dystrophy (FSHD), Limb Girdle Muscular Dystrophy (LGMD), or Congenital Muscular Dystrophy (CMD); a central or spinal muscular atrophy such as: Amyotrophic Lateral Sclerosis (ALS) or Spinal Muscular Atrophy (SMA); a neurogenic muscular atrophy such as: Charcot-Marie-Tooth peripheral neuropathy; a congenital myopathy such as: Myotubular myopathy; an ‘idiopathic’ muscle wasting condition such as: Inclusion Body Myositis (IBM) or age-related sarcopenia.
- The myostatin pathway inhibitor may be a myostatin antagonist or an ActRII antagonist. In embodiments of the invention the myostatin pathway inhibitor may be a myostatin inhibitor.
- Suitable myostatin antagonists include anti-myostatin antibodies, myostatin decoys, follistatin, or follistatin analogues. Myostatin pathway inhibitors may also include abolishing or impeding the myostatin pathway through the use of siRNA, shRNA, antisense oligonucleotides, miRNA interference through gene silencing using exon skipping or nuclease-mediated invalidation through CRISPR or TALEN. Alternatively, the myostatin antagonist may be provided in the form of myostatin pro-peptide overexpression or altered myostatin pro-peptide expression, either or both of which may be delivered by gene therapy. Altered myostatin pro-peptide expression may comprise tighter binding of the pro-domain to the mature myostatin protein, thereby inhibiting cleavage of the pro-peptide into mature myostatin, and thereby inhibiting myostatin function.
- Suitable ActRII antagonists include anti-ActRII antibodies, ActRII decoys or inhibitors of effectors downstream of the ActRII, as well as small molecules down-regulating myostatin. In embodiments of the invention, soluble ActRII may be administered to outcompete the receptor, acting as a decoy for the mature myostatin protein.
- In embodiments of the invention the myostatin pathway inhibitor may be selected from one or more molecules known to block myostatin pathways including but not limited to PF06252616, FS344, Bimagrumab, ACE-083, ACE-031, ACE-2494, AAV1-FS344, AAV9-FS344, BMS-986089 or MYO-029.
- GDF11 pathway inhibition may be achieved through anti-GDF11 antibodies or human IgG1 Fc-fused GDF11 propeptide.
- In a further aspect the present invention provides a dystrophin or myotubularin (MTM1) gene or pathology correcting therapy and a myostatin pathway inhibitor for use in treating muscle atrophy or a muscle wasting condition.
- As mentioned above, muscle atrophy or a muscle wasting condition will lead to muscle fibres becoming dormant, rendering them unable to respond to a myostatin pathway inhibitor. Surprisingly, the present inventors have found that this effect of muscle atrophy or a muscle wasting condition can be reversed utilising gene therapy or pathology correcting therapy. While not being directly associated with myostatin, MTM1 encodes a phosphatidylinositol-3-phosphatase and is required for muscle cell differentiation. Surprisingly, reinstating MTM1 gene expression leads to reactivation of myostatin synthesis by muscle fibres. The muscle is then able to respond to a myostatin pathway inhibitor and improvements in myogenesis, i.e. muscle cell growth and differentiation, alleviate or reverse the effects of the muscle atrophy or muscle wasting condition. Similar effects can be achieved by reinstating dystrophin gene expression. Dystrophin deficiency underlies the pathology of Duchenne and Becker muscular dystrophies and reinstating dystrophin gene expression can lead to reactivation of myostatin synthesis by muscle fibres, rendering them able to respond to a myostatin pathway inhibitor.
- The muscle atrophy or a muscle wasting condition may be any genetically determined neuromuscular condition where a gene therapy, a cell therapy, or a small molecule therapy is capable of stopping or reverting the underlying pathogenic mechanism. All genetic muscle disorders listed above may be suitable for treatment.
- Suitable myostatin pathway inhibitors and forms and routes of administration include those described above in relation to other aspects of the invention.
- A pathology correcting therapy may include a cell or small molecule therapy capable of stopping or reversing the pathology underlying the muscle atrophy or muscle wasting condition. For example, a small molecule therapy may be used to provide an indirect gene therapy, acting by targeted promotor stimulation or splicing modification.
- Gene therapy may be provided in the form of a recombinant viral vector supplying or partially or fully correcting a missing gene such as MTM1 or the dystrophin gene, or suppressing a damaging gene expression such as SOD-1 through RNA interference or out-of-frame exon skipping of the damaging gene. Suitable viral vectors will be familiar to the skilled person and include a retrovirus, an adenovirus, a lentivirus, herpes simplex virus, and adeno-associated virus. Other viral vectors are envisaged.
- The gene or pathology correcting therapy and myostatin pathway inhibitor may be administered separately, simultaneously or sequentially. Preferably, the gene or pathology correcting therapy is administered prior to the myostatin pathway inhibitor. The gene or pathology correcting therapy may be administered at least two weeks, or at least three weeks, or at least four weeks prior to the myostatin pathway inhibitor. In embodiments of the invention the gene or pathology correcting therapy may be administered at least one month or at least two months or at least three months prior to the myostatin pathway inhibitor. The time period will be dependent on the underlying pathology and can be determined by a medical practitioner. Once the target muscle(s) are sufficiently healthy to start synthesising myostatin, the myostatin pathway inhibitor can be administered. Muscle biopsies and/or systemic samples as described above may be utilised to monitor levels of essential actors of the myostatin pathway in the target muscle(s).
- The present invention also provides a method for improving or monitoring dystrophin or MTM1 gene or pathology correcting therapy, the method comprising determining a level of myostatin and/or ActRII and/or follistatin in a sample obtained from a subject.
- Preferably the level of myostatin and/or follistatin is compared to a threshold as described above. Optionally, if the level of myostatin is below the threshold and/or if the level of follistatin is above the threshold, at least one further round of gene or pathology correcting therapy may be administered.
- In a still further aspect, the present invention provides a dystrophin or MTM1 gene or pathology correcting therapy for use in treating muscle atrophy or a muscle wasting condition in a subject, wherein the subject is characterised by having a myostatin and/or ActRII level lower than a threshold level.
- The subject may be characterised by having a systemic or local level of myostatin or ActRII that is lower than a threshold level. Threshold levels can be determined as described above. Suitable samples may be obtained and/or measured as described in relation to the aspects of the invention. In embodiments of the invention, the subject may be characterised by having at least one skeletal muscle that does not express ActRII at normal levels, said muscle being determined by at least one muscle biopsy indicating reduced levels of active ActRII.
- The effect of myostatin on skeletal muscle is exclusively mediated by mature myostatin acting on ActRII. Consequently, if skeletal muscle expresses little or even no ActRII it cannot be ‘sensitive’ to the effects of mature myostatin on promoting muscle growth.
- The present invention also provides a method for determining anabolic capacity of the skeletal muscle system of a subject, the method comprising: (a) determining a level of myostatin and/or follistatin in a systemic sample obtained from the subject; and/or (b) determining a level of myostatin and/or ActRII and/or follistatin in at least one skeletal muscle biopsy obtained from the subject; wherein if (i) the level of myostatin in the systemic sample is lower than a threshold and/or if the level of follistatin in the sample is higher than a threshold; and/or (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is lower than a threshold level and/or if the level of follistatin in the at least one biopsy sample is higher than a threshold level, the anabolic capacity of the skeletal muscle system is compromised, indicating the existence of a muscle wasting process in the subject. Threshold levels can be determined by comparison with an aged matched population without significant medical disorders.
- Myostatin deficiency results in muscle hypertrophy and shifts muscle from aerobic toward anaerobic energy metabolism, resulting in reduced mitochondrial respiration, reduced expression of peroxisome proliferator-activated receptor (PPAR) transcriptional regulators, increased endonuclease activity and exercise induced lactic acidosis. This results in diminished exercise capacity and increased fatigability. This effect is exclusively regulated through myostatin signalling via ActRII. The essential effectors of the myostatin pathway are therefore biomarkers of the anabolic homeostatic state of the muscular tissue and can be used for pre-symptomatic monitoring of muscle atrophy or muscle wasting conditions, and/or for monitoring the effects of therapy on such conditions.
- The method for determining anabolic capacity of the skeletal muscle system of a subject may further comprise comparing one or more of the levels of myostatin, ActRII receptor and/or follistatin to thresholds to determine the activity of the muscle wasting process. Optionally the subject may be treated with a dystrophin or MTM1 gene or pathology correcting therapy and/or a myostatin pathway inhibitor.
- The present invention also provides a method for determining inclusion of subjects into a clinical trial for evaluation of a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or ActRII and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, admitting the subject to the clinical trial.
- Additionally or alternatively, the method may comprise determining levels of activin A in the muscle biopsy and systemic samples, wherein if the level of activin A is higher than threshold levels for each sample, the patient is admitted into the clinical trial. Myostatin and activin A are both biomarkers of muscle health and atrophy. Activin A levels are indicative of myostatin levels and can therefore provide an indication of whether a subject is likely to respond to an anti-myostatin approach. Similarly, myostatin levels are indicative of activin A levels and can therefore provide an indication of whether a subject is likely to respond to an anti-activin A approach.
- The method for determining inclusion of subjects into a clinical trial for evaluation of a myostatin pathway inhibitor may further comprise commencing the clinical trial and administering the myostatin pathway inhibitor or a placebo control to the subject.
- The present invention additionally provides a method for determining whether a patient having or suspected of having spinal muscular atrophy (SMA) will respond to treatment, the method comprising: determining a level of myostatin and/or follistatin and/or Growth differentiation factor 11 (GDF11) in a systemic sample obtained from the patient; wherein a level of GDF11 above a threshold is associated with SMA; and wherein if the level of myostatin is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold, the patient will respond to treatment.
- Spinal muscular atrophy (SMA) is a rare neuromuscular disorder characterised by loss of motor neurons and progressive muscle wasting, often leading to early death. The disorder is caused by a genetic defect in the SMN1 gene, which encodes SMN, a protein widely expressed in all eukaryotic cells and necessary for survival of motor neurons. Lower levels of the protein results in loss of function of neuronal cells in the anterior horn of the spinal cord and subsequent system-wide atrophy of skeletal muscles.
- Spinal muscular atrophy manifests in various degrees of severity, which all have in common progressive muscle wasting and mobility impairment. Proximal muscles and respiratory muscles are affected first. Other body systems may be affected as well, particularly in early-onset forms of the disorder. SMA is the most common genetic cause of infant death. Due to the severity of its effects (which may affect the respiratory muscles) and the age of patients (who are commonly in infancy), it is often not possible to obtain a muscle biopsy sample, especially if a general anaesthetic would be required. However, the present inventors have determined that there is an association between abnormally high levels of systemic GDF11 and SMA. This may be an indication that GDF11 can be used in combination with other systemic markers of the myostatin pathway to determine whether a patient will be suitable for therapy to treat SMA.
- GDF11, also known as bone morphogenetic protein 11 (BMP-11), is a myostatin(GDF8)-homologous protein that acts as an inhibitor of nerve tissue growth. Like myostatin, GDF11 binds to the ActII receptor. GDF11 has been shown to suppress neurogenesis through a pathway similar to that of myostatin, including stopping the progenitor cell-cycle during G-phase. The similarities between GDF11 and myostatin imply that similar signalling pathways are used to control tissue growth during both muscular and neural development.
- As described above, suitable systemic samples for use in methods of the present invention include bodily fluid samples, such as a whole blood sample, a serum sample, a plasma sample or a urine sample. Preferably the systemic sample is a serum sample.
- The method may further comprise administering a treatment for SMA, such as Nusinersen, to a patient determined to respond to the treatment.
- Additionally or alternatively, the method may comprise determining levels of GDF11 in a subject with spinal muscular atrophy and, if levels are above a threshold of above 50-100% of normal, treating such a subject with a GDF11 inhibitor.
- As described above, the patient and/or subject is preferably a mammal, including a human, and may be of any age or a paediatric or a geriatric patient. The patient may be an infant. In embodiments of the invention the patient may have or be suspected of having SMA.
- Any number of the features of the various aspects of the invention may be combined with any number of features of any other aspects and in any embodiment.
- The invention will now be described in detail, by way of example only, with reference to the figures.
-
FIGS. 1A-1D : Circulating levels of GDF8, FSTN, ACTIVIN A and GDF11Circulating levels of either GDF8 (A), FSTN (B), ACTIVIN A (C) and GDF11 (D) were measured in healthy control (Ctrl, N=9), Becker Muscular Dystrophy (BMD, N=6), Spinal Muscular Atrophy (SMA, N=4), Duchenne Muscular Dystrophy (DMD, N=4), Inclusion Body Myositis (IBM, N=54), Myastenia Gravis (MG, N=12) or Facioscapulohumeral Dystrophy (FSHD, N=13) patients. Horizontal lines are medians, the extremities of the boxes are delimitated by the first and third quartile, and the whiskers correspond to the 10th and 90th percentile. A multiparametric analysis of variance and a Newman-Keuls post hoc test were performed. Degree of freedom=6. -
FIGS. 2A-2C : Myostatin pathway in muscle biopsiesmRNA levels of either MSTN, FSTN, or ACTRIIB were measured by RT-qPCR in in healthy controls (Ctrl, N=9), Becker Muscular Dystrophy (BMD, N=6), Duchenne Muscular Dystrophy (DMD, N=17), Inclusion Body Myositis (IBM, N=17), Facioscapulohumeral Dystrophy (FSHD, N=13) or Limb Girdle Muscular Dystrophy (LGMD, N=11) patients. Horizontal lines are medians, the extremities of the boxes are delimitated by the first and third quartile, and the whiskers correspond to the 10th and 90th percentile. A multiparametric analysis of variance and a Newman-Keuls post hoc test were performed. Degree of freedom=6. -
FIGS. 3A-3I : Myostatin network in Mtm1-KO mice. The tibialis anterior (TAs) of 3 week-old Mtm1-KO mice were injected with either PBS (A, F, G, H, I), an AAV vector coding the myostatin pro-peptide D76A mutant (PropD76A) (A), an AAV vector coding Mtm1 (Mtm1) (F, G, H, I), or an AAV coding both Mtm1 and propD76A (F, G, H, I). Two weeks later, mice were sacrificed and the TAs were weighed (A, F). The weights (B), Msnt mRNA (C), Fsnt mRNA (D) or ActRIIb mRNA (E) were measured at 14, 21 or 30 days in the TAs of either Mtm1-KO mice (KO) or wild type littermates (WT). -
FIG. 4A : Natural history of circulating myostatin levels in healthy and Golden Retriever muscular dystrophy (GRMD) dogs. While the myostatin level increases in healthy dogs as they age, it decreases in GRMD dogs. At the age of 2.5 months the myostatin level is sufficient to distinguish heathy and GRMD dogs.FIG. 4B : Locoregional injection of an AAV vector coding a dog microdystrophin. The injections restrict the myostatin decrease observed in GRMD dogs.FIGS. 4C and 4D : The systemic injection of a low or high dose of an AAV vector coding a dog microdystrophin is not sufficient to increase myostatin levels in GRMD dogs. Even after injection, myostatin level never reaches the levels observed in the WT animals. However, after high dose injection, myostatin level is maintained until the age of 20 months, while after low dose injection, myostatin level slowly decrease. Very interestingly, at the age of 25 months, myostatin levels suddenly fall and reach the levels observed in the non-injected animals. This probably highlights the moment when microdystrophin level is decreasing and the effect of AAV-microdystrophin therapy is waning. Indeed, after AAV injection, the muscle degeneration/regeneration cycle continues in the dogs because the treatment does not cure the animals. The microdystrophin transgene is therefore slowly cleared from the muscles leading to a decrease in microdystrophin and myostatin expression. -
FIG. 5 : The different elements ofFIGS. 4 are combined. A difference in circulating myostatin levels is observed in the low dose, high dose and untreated groups. The more microdystrophin is expressed, the higher the myostatin levels are. - The collection of sera and biopsies were approved by the “Comité de Protection des Personnes” Paris VI and the French regulatory agency (ANSM) (CCP#99-12, ID RCB 2012-A01277-36), the research and Development Office (#DN 12DN29), and the East Central London Research Ethics Committee 1 (
reference number 10/H0721/28). The characteristics of the patients are described in tables 1 and 2. -
TABLE 1 Characteristics of patients’ sera Ctrl (n=9) BMD (n=6) SMA (n=4) DMD (n=5) IBM (n=54) MG (n=12) FSHD (n=13) Age (years) Mean Range 34.2 23.1-45.3 18.3 7.2-48.7 11.0 8.9-12.9 9.2 6.0-13.9 64.9 41.3-87.1 46.6 16.5-64.3 46.8 14.5-61.2 Gender Female 6 - 1 - 17 7 4 Male 3 6 3 5 37 5 9 Age of onset Mean - Early Childhood Infant Early Childhood 56.5 37.3 20 Range - 35-82 14.5-62.3 2-49 -
TABLE 2 Characteristics of patients’ biopsies Ctrl (n=9) BMD (n=6) DMD (n=17) IBM (n=17) FSHD (n=13) LGMD (n=11) Age (years) Mean 43.2 32.5 9.7 70.5 45.0 28.8 Range 24.0-69.0 1.6-61.3 0.8-17.7 56.9-81.0 13.0-79.4 8.6-57.9 Gender Female 6 - - 3 5 5 Male 3 6 17 14 8 6 Age of onset (years) Mean - 23.8 3.3 65.4 27.2 23.3 Range - 5-48 2-6 45-78 16-40 2-55 - Mice were handled according to French and European legislation on animal care and experimentation, and protocols were approved by the institutional ethical committee. The constitutive knockout of the myotubularin gene (Mtm1-KO, also named BS53d4-129pas) was described previously (Buj-Bello et al, 2002). Wild-type littermate males were used as controls.
- A
recombinant serotype 1 AAV vector containing mutated myostatin propeptide D76A under the CMV promoter (AAV-PropD76A) was produced as previously described (Bartoli et al, 2007). Mouse Mtm1 cDNA (AF073996, NCBI) was cloned in the AAV expression pGG2-DES plasmid, which contains the human desmin promoter.Recombinant serotype 1 viral particles (AAV1-Mtm1) were obtained by a tri-transfection procedure from HEK293 cells as previously described (Buj-Bello et al, 2008). Vector titers were expressed as viral genomes per ml (vg/ml). - AAV vectors were intramuscularly delivered to 3 week-old KO mice and age matched wild type males. Mice were anesthetized by intraperitoneal injection of 5 µL/body gram of ketamine (20 mg/mL, Virbac) and xylazine (0.4%, Rompun, Bayer). Tibialis anterior (TA) muscles were injected with 3.5 × 109 vg of AAV-CMV- PropD76A, 5 × 109 vg of AAV-Mtm1 or sterile phosphate buffer saline (PBS) solution. Muscles were dissected 14 days after injection and frozen in either liquid nitrogen-cooled isopentane or liquid nitrogen for histological and molecular assays.
- Peripheral venous blood was collected from healthy and patients’ volunteers using serum separator tubes (10 mL). After 30 minutes on the benchcoat at room temperature, the tubes were centrifuged at 2000 rpm for 10 min at 4° C. The collected serum (5 mL) was aliquoted and stored at -80° C. until further use. The concentrations of either GDF8, FOLLISTATIN, GDF11 or ACTIVIN A in the sera were measured using an ELISA kit (respectively # DGDF8, # DFN00, # DY1958 and # DAC00B R&D Systems Europe, Ltd, Abingdon, United Kingdom) according to the manufacturer’s instructions. The optical density was measured using a microplate reader (
Infinite 200 Pro, Tecan Group Ltd., Männedorf, Switzerland). Importantly, the myostatin immunoassay was designed to recognize mature GDF8. According to the manufacturer, no significant cross-reactivity or interference was observed in the presence of 50 ng/ml (20 times more than the highest value measured in our experiment) of different proteins including the GDF8 propeptide, GDF11 or GDF15. We have experimentally confirmed this result by using 4000 pg/ml of recombinant GDF11. The absence of cross reactivity with FOLLISTATIN (8000 pg/ml), ACTIVIN 1 (4000 pg/ml) and GASP-1 (4000 pg/ml) was also experimentally validated. - For murine samples, Total RNA was purified from muscles of 5 week-old males using TRIzol reagent (Life Technologies, Saint Aubin, France) according to manufacturer’s instructions. RNA concentration was measured by spectrophotometry (OD 260 nm) using a nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and RNA integrity was verified by electrophoresis using ethidium bromide. After DNAse treatment (Ambion), RNA was reverse transcribed using Super Script II RNase H Reverse Transcriptase (Invitrogen) in the presence of Random Primers (Promega). Real-time PCR was performed at 60° C. as melting temperature and with primers described in Table 3 using an ABI Prism 7900 apparatus (Applied Biosystems) in a final volume of 25 µl with reverse transcriptase, forward and reverse primers (0.5 nmol/ml) and SYBRGreen Mastermix (Roche, Basel, Switzerland).
-
TABLE 3 Oligonucleotides used in this study Gene symbol Accession no° Name 5′ 3′ SEQ ID NO Amplicon length Actb NM_007393.5 b-actin_F CTGGCTCCTAGCACCATGAA 1 123 b-actin_R CTGCTTGCTGATCCACATCT 2 Activin A NM_008380.2 Activin A -F CACACTTCTGCACGCTCCAC 33 92 Activin A -R TTTGCCGAGTCAGGCACAG 34 Tubb5 NM_011655.5 b-tubulin_F CCTTCATTGGAAACAGCACA 3 222 b-tubulin_R CCTCCTCTCCGAAATCCTCT 4 Gapdh NM_0012897 26.1 Gapdh_F TTGTGATGGGTGTGAACCAC 5 283 Gapdh_R TTCAGCTCTGGGATGACCTT 6 Gdf11 NM_010272 Gdf11 - F ATCAGCCGGGAGGTAGTGAA 35 159 Gdf11 - R CTGGGCCATGCTTATGACCGT 36 Hprt NM_013556.2 Hprt1_F GCAAACTTTGCTTTCCCTGG 7 85 Hprt1_R ACTTCGAGAGGTCCTTTTCACC 8 Rplp0 NM_007475.5 P0_F CTCCAAGCAGATGCAGCAGA 9 87 P0_R ATAGCCTTGCGCATCATGG 10 Acvr2b NM_007397.3 ActrIIB_F GCTCAGCTCATGAACGACT 11 68 ActrIIB_ R CTCTGCCACGACTGCTTGT 12 Fst NM_0013013 73.1 Fstn_F CTCTTCAAGTGGATGATTTTC 13 345 Fstn_R ACAGTAGGCATTATTGGTCTG 14 Mstn NM_010834.3 Mstn_F GCACTGGTATTTGGCAGAGTA 15 345 Mstn_R CACACTCTCCTGAGCAGTAAT 16 INHIBIN A ENST000002 42208.4 F-ACTIVIN A TTATGGAGCAGACCTCGGAG 37 75 R-ACTIVIN A AAATCTCGAAGTGCAGCGTC 38 B2M NM_004048 F_B2M CTCTCTTTCTGGCCTGGAGG 17 67 R_B2M TGCTGGATGACGTGAGTAAACC 18 GAPDH ENST000002 29239 F-GAPDH2 AAGGTGAAGGTCGGAGTCAACGG 19 199 R-GAPDH2 TGACAAGCTTCCCGTTCTCAGCC 20 GUS ENST000003 04895 F-GUS CTCATTTGGAATTTTGCCGATT 21 81 R-GUS CCGAGTGAAGATCCCCTTTTTA 22 RPLPO F-P0 TCCAGGCTTTAGGTATCACCAC 23 94 ENSG000000 89157 R-P0 GCTCCCACTTTGTCTCCAGTC 24 PPIA ENST000003 55968 F-PPIA CCTAAAGCATACGGGTCCTG 25 133 R-PPIA TTTCACTTTGCCAAACACCA 26 ACVR2B ENST000003 52511 F52-AcvRIIb CTCCTCTGGGGATCGCTGT 27 84 R135-AcvRIIb CTCCCAGTTGGCGTTGTAGT 28 FST ENST000002 56759 F1-FST CGGCTGAGCACCTCGTG 29 155 R1-FST TTCTTGTTCATTCGGCATTT 30 GDF11 ENST000002 57868.9 F-GDF11 ATTGGCAGAGCATCGACTTC 39 182 R-GDF11 TTTTGTGTTCTCTAGGACTCG 40 MSTN NM_005259 F-972 TTTTACCCAAAGCTCCTCCA 31 258 R-3017 GAGTCTCGACGGGTCTCAAA 32 MYL1 ENST000003 52451 F-MYL1 GCAATGAAGAGCTGAATGCCA 41 126 - For human samples, cryopreserved tissues were transferred in tube containing 1.4 mm ceramic beads (Precellys, Bertin Corp, Maryland, United State) plus 1 mL of Trizol (Life technologies, Saint Aubin, France) and shaken 3 times at 5700 rpm for 30 s. Between each cycle, tubes were incubated in ice during at least 1 min. Total RNAs were extracted using trizol according to the manufacturer’s protocol (Life technologies, Saint Aubin, France). The quantity of RNA was determined using a nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The reverse transcription and polymerase chain reaction (PCR) were described previously 29. qPCRs were performed on a LightCycler 480 Real-Time PCR System (Roche, Meylan, France) in a final volume of 4 µl with 0.4 µl of reverse transcriptase (RT) product, 0.18 µl each of forward and reverse primers (20 pmol/ml) and 4.5 µl of SYBRGreen Mastermix (Roche, Basel, Switzerland). After qPCR, the PCR products were run on a 2% agarose gel and were cloned using the Topocloning kit (Life Technologies, Saint Aubin, France) and sequenced. Primers used in this study are described in Table 3.
- Quantitative PCR (qPCR) was designed according to the
MIQE standards 30. Among the 87 items to review, 57 were classified as essential. All were followed. In particular, to determine the best human housekeeping gene, 5 genes were evaluated: B2M, GAPDH, GUS, PO and PPIA. A MANOVA test has demonstrated that none of these genes were suitable for housekeeping since significant statistical changes were observed between the different groups. GUS, PO and PPIA were then chosen to calculate the expression normalization factor for each sample using geNorm software (V3.5). To determine the best housekeeping mouse gene, 6 genes were evaluated: Gapdh, Po, Hprt1, β-actin, β-tubulin and 18S and Po was chosen. - A one-way ANOVA was used for all the experiments, followed by the Fisher’s Least Significant Difference multiple comparison test. Differences were considered to be statistically different at p *<0.05; **<0.01; ***<0.001
- Human myostatin serum concentrations are lowest in the most marked muscle atrophying diseases
- Serum concentrations of MSTN, FSTN, GDF11 and ACTIVIN A were determined in patients with different pathologies affecting skeletal muscles (summarized in Table 1). BMD (Becker Muscular Dystrophy) and DMD (Duchenne Muscular Dystrophy) share similar clinical signs and symptoms including muscle weakness and atrophy but in BMD, symptoms are milder and patients have a later onset. Both DMD and BMD are caused by different mutations in the DMD gene but mutations in DMD patients lead to an absence of any functional dystrophin protein whereas mutations in BMD patients lead to a less functional protein. SMA (Spinal Muscular Atrophy) is characterized by a loss of motor neurons leading to muscle wasting often leading to premature death. IBM (Inclusion-Body Myositis) is the most common age-related muscle disease in elderly and is a slowly progressive inflammatory and degenerative myopathy characterized by chronic muscle weakness and atrophy. FSHD (Facioscapulohumeral Dystrophy) is the most common muscular dystrophy in adults characterized by the selective atrophy of groups of muscles. Finally, MG (Myasthenia Gravis) is the most common primary disorder of neuromuscular transmission, caused by antibodies to the acetylcholine receptor leading to muscle weakness usually without severe muscle atrophy. For ACTIVIN A, no differences were observed but a trend to a lower expression in SMA and DMD patients (p=0.06 for both) was noted. No modification of GDF11 was noted, except in SMA sera in which a massive overexpression was observed. Concerning GDF8, in the most atrophic (SMA) and most wasting (DMD) muscle diseases studied a two-fold or higher decrease of circulating MSTN was observed (SMA 30.6% ± 13.7 and DMD 50.6% ± 17.18 MSTN compared to controls respectively) (
FIG. 1A ). Associated with this MSTN decrease, an important trend to an increase of circulating FSTN was observed (SMA 135.6% ± 71.3 and DMD 189.4% ± 35.2 compared to controls respectively) (FIG. 1B ). - BMD, IBM and FSHD patients, who clinically show a less pronounced muscle atrophy, have more circulating myostatin than DMD and SMA patients but less than controls (BMD 71% ± 23.7, IBM 71% ± 55.6 and FSHD 66% ± 35 compared to controls respectively). The levels of circulating FSTN were not increased in BMD patients (85.5 % ± 22.4) whereas a trend to an increase was observed in both IBM and FSHD patients (146.3 ± 70.9 and 145.8 ± 72.8). In MG patients, who do not show any atrophy, no modification of MSTN nor FSTN was observed. Importantly, regarding all the effectors of the myostatin pathway, an important variation across samples is observed in IBM and FSHD patients, suggesting that the myostatin network may be significantly down-regulated in some patients whereas there is still preserved myostatin expression in others. A correlation test was performed between MSTN and FSTN levels, but no correlation was found.
- The MSTN pathway is down-regulated at mRNA level in the most atrophying diseases As MSTN is mainly produced by skeletal muscle, the mRNA expression levels of several genes implicated in the myostatin pathway were investigated in muscle biopsies (summarized in Table 2). Unfortunately, SMA biopsy could not be studied since the diagnosis is essentially genetic and a muscle biopsy is not normally performed in SMA. A massive down-regulation of MSTN was observed in both the DMD and IBM patients as only 29% and 12% of the respective mRNA levels were detectable (
FIG. 2A ). At the same time, FSTN was up-regulated by 2.7 fold in IBM patients (p= 0.039) (FIG. 2B ). Interestingly, the myostatin receptor ActRIIB was strongly down-regulated in both DMD (30% of residual mRNA, p=0.014) and IBM (40% of residual mRNA, P=0.07) but up-regulated in FSHD (+28%, p=0.006) (FIG. 2C ). In LGMD and BMD, no significant modification of muscle MSTN, FSTN or ACTRIIB was observed. An important variability across LGMD and BMD samples was observed but the most atrophying diseases (DMD, SMA) showed again a general down-regulation of the myostatin pathway. No correlation was found between MSTN, ACTRIIB and FSTN in all individual diseases. However, concerning FSHD patients, FSHD1 patients express less MSTN than FSHD2 patients (p=0.048), but no difference was observed in FSTN (data not shown). FSHD2 patients showed a trend to express more ACTRIIB than FSHD1 (+120%, p=0.08). - Expression of myostatin is crucial for a successful anti-myostatin approach
- In order to determine whether or not the endogenous expression level of the myostatin pathway could impact the success of anti-myostatin approaches, we used the Mtm1-KO mouse model. We have chosen the Mmt1-KO model because X-linked myotubular myopathy (XLMTM), which is a severe congenital disease due to mutations in the myotubularin coding gene MTM1, is characterized by generalized muscle hypotrophy and weakness and this mouse model recapitulates the muscle atrophy. Moreover, the XLMTM muscle phenotype can be corrected by AAV-mediated gene replacement therapy in the Mtm1-KO mouse model of the disease.
- Three week-old myotubularin KO (Mtm1-KO) and wild type (WT) mice were intramuscularly (in the tibialis anterior (TA)) injected with an AAV coding the myostatin pro-peptide D76A mutant (AAV8PropD76A). While an increase in muscle weight was observed in the WT mice after 1 injection (123.8% ± 12.7% of residual mRNA, p=1.16.10e-10), no muscle growth was observed in the Mtm1-KO mice (93.7% ± 26.9 of residual mRNA, p>0.05) (
FIG. 3A ). Because at 3 weeks, Mtm1-KO mice already show an important loss of muscle weight compared to WT littermates (84% ± 12% of residual mRNA at 14 days, 50% ± 8.1% at 21 days and 34.5% ± 7.2% at 30 days in tibialis anterior,FIG. 3B ), the expression level of the myostatin network was investigated. A strong down expression of Mstn (47.6% ± 18.6% of residual mRNA at 14 days, 22.5% ± 7.8% at 21 days and 25% ± 6.5% at 30 days,FIG. 3C ), associated with a massive up-regulation of Fstn (159% ± 44.9% of residual mRNA at 14 days, 567% ± 201% atday 21 and 768% ± 190% atday 30,FIG. 3D ) was observed. ActRIIb expression was only barely affected (FIG. 3E ). These results suggest that inhibiting the myostatin pathway might not be a successful therapeutic strategy in the Mtm1-KO mice at the time point of our analysis because the myostatin pathway is already dramatically down-regulated with 4.4 fold decrease of Mstn mRNA and a 5.6 fold increase of Fstn mRNA in the TA of 3 weeks old Mtm1-KO mice. - The tibialis anterior of WT or Mtm1-KO mice were next intramuscularly injected with either an AAV coding the Mtm1 gene (AAV-Mtm1) or a combination of the AAV-Mtm1 gene and the AAV16 PropD76A. In the presence of the Mtm1 protein, muscle histology was greatly improved with an increase of cross-sectional fiber size, and an improved intracellular architecture revealed after NADH-TR staining (data not shown). The abnormal localizations of the dihydropyrine 1α receptor (DHPR1α) and ryanodine receptor 1 (RYR1) were partially restored. In the Mtm1-KO mice, the muscle mass was improved in the presence of the AAV-Mtm1 (148.1% ± 12.9% of residual mRNA, p=5.3 10e-6 compared to the Mtm1 KO injected with PBS) whereas no modification of muscle mass was observed in the WT mice (
FIG. 3F ). Interestingly, the presence of both AAV-Mtm1 and AAV-PropD76A allowed a further increase in muscle mass in the Mtm1-KO mice (179% ± 25.2%, p=7.15 10e-11, compared to the TAs injected with PBS,FIG. 3F ). A similar effect was observed in the WT mice (123.3% ± 6.8%, p=8.5 10e-9 compared to the WT mice injected with PBS). Importantly, in both Mtm1-KO and WT mice, the simultaneous injection of AAV-PropD76A + AAV-Mtm1 led to a higher increase in muscle mass than AAV-Mtm1 alone (FIG. 3F ). - To determine if the myostatin pathway was restored by the expression of Mtm1 in the Mtm1-KO mice, the expression levels of Mstn, Fstn and ActRIIb were analyzed in the transduced TAs. An increase of Mstn, associated with a decrease of Fstn was observed in the presence of Mtm1 (
FIGS. 3G, H ), without modification of ActRIIb level (FIG. 3I ). The combination of myostatin pathway inhibition and Mtm1 rescue enhanced both the Mstn increase and the Fstn decrease (FIGS. 3G, H ). These results suggest that the expression of Mtm1 in the Mtm1-KO mice leading to a 2.4 increase of Mstn and a 2.8 decrease of Fstn was sufficient to enable an anabolic effect of the myostatin propeptide on muscle mass. The muscle atrophy observed in the Mtm1-KO mice may not be due to an up-regulation of the myostatin pathway but rather a consequence of the absence of myotubularin. - During the past 12 years at least 15 clinical trials aimed at inhibiting the myostatin pathway have been carried out to improve muscle mass and function in muscular diseases, and several of these studies are still underway (https://clinicaltrials.gov/). Different pathologies were targeted among them BMD, DMD, LGMD, IBM and FSHD. The concept of anti-myostatin therapy for neuromuscular diseases has been based on the postulate that inhibiting this pathway in patients might lead to an increase in muscle mass and muscle strength/function as it does in normal muscle, which implies that the level of circulating myostatin is high enough to be down-regulated by such a therapeutic approach. However, the results were disappointing: (i) the injection of MYO-29, a recombinant human neutralizing antibody to myostatin, in adult muscular dystrophies (BMD, FSHD and LGMD) did not improve any of the outcome measures (strength, lean body mass, muscle volume). (ii) DMD patients treated with ACE-031, a soluble form of activin type IIB receptor, showed a very slight increase in total body lean mass (+4.1% compared to +2.6% in the placebo group) and a non-statistically significant trend for maintenance of 6 minute walk test was observed in the ACE-031 treated group, although the study had to be interrupted after 12-16 weeks due to safety concerns. (iii) For sIBM patients treated with bimagrumab, a human monoclonal antibody targeting activin receptors IIA and IIB, an increased muscle and lean body mass was observed, as well as an improvement in the 6-minute walking test after 6 month treatment in a
single dose phase 2 study. However, Novartis has recently announced that bimagrumab had not met its primary endpoint (6-minute walk distance) in a late-stage Phase2b/3 study. (iv) Only one approach inphase 2 showed preliminary promising results: BMD patients, multiply intramuscularly injected in 3 of the 4 muscles forming the quadriceps with an AAV vector encoding the follistatin isoform FS344 showed an improvement of the 6 minute walk test by 11.5% at 6 months post injection. Currently, several clinical trials are underway and results are expected next year. - Different possibilities could explain this absence of functional improvement, among them the drug pharmacokinetic/pharmacodynamic (PK/PD) in the conditions studied so far in humans. A retrospective analysis demonstrated that central clearance of MYO-029 in humans is greater than 2 fold than typical IgG1 mAbs and PK/PD analyses in monkeys suggesting that peak and steady state exposures in the MYO-029 trial might achieve only 50% and 10% of the maximum effect seen in monkeys. This would explain why the MYO-029 had a low probability to induce a muscle mass increase in patients. Another explanation could be the lack of specificity of the drugs themselves, MSTN and GDF11 sharing 90% in their mature region for example. Finally, MSTN might not be the only ligand implicated in muscle growth to bind ACTRIIB, as it was demonstrated that blocking ActRIIb in Mstn deficient mice further enhances muscle mass.
- In our study, we have explored another confounding possibility based on the expression levels of circulating and muscle-endogenous proteins implicated in the myostatin pathway. Recently, Burch et al. (2017) have published that serum myostatin concentrations are reduced in patients with muscle diseases. They concluded that because myostatin is mainly produced by muscle tissue, these reduced circulating myostatin may reflect the net loss of functional muscle mass.
- Our data however do not support this hypothesis. Indeed, we have observed that whole myostatin pathway is strongly altered in the most atrophying neuromuscular diseases, at both mRNA and protein levels, and that the lower expression of serum myostatin is associated with a reduced muscle expression of MSTN mRNA. These results indicated that reduced circulating myostatin levels are not, or at least not only, the reflexion of muscle loss but represent an altered myostatin homeostasis of the diseased tissue. In addition, the muscle atrophy observed in DMD patients is not the consequence of an activation of the myostatin pathway. On the contrary, our data indicate that the myostatin pathway may be intrinsically down-regulated in atrophying or wasting muscle diseases to counterbalance the wasting process. This could explain the apparent contradictory results in mice and humans regarding the efficacies of anti-myostatin approaches. Indeed, the outcome of a clinical trial in DMD patients was not encouraging, while myostatin pathway blockade has been successful in mdx mice. Despite the fact that Duchenne patients and mdx mice share a mutation in the same gene, no important muscle atrophy is observed before 6 months of age in the mdx mouse and experiments are usually performed before this age. Moreover, even if myostatin levels are lower in mdx mouse than in wild type mouse, the endogenous circulating myostatin level is at least 50 times higher in mice than in humans. This could be one of the reasons why anti-myostatin approaches in the mdx model were successful.
- Finally, one of the most important questions raised by our work concerns the usefulness of blocking the myostatin pathway in neuromuscular diseases in general. In slowly progressive pathologies such as BMD or FSHD, an important variability of both myostatin and follistatin circulating proteins is observed across samples, suggesting that at least some patients may be eligible for an anti-myostatin approach. However, in the most wasting neuromuscular diseases such as DMD, the whole myostatin pathway is down-regulated. Interestingly, in the Mtm1-KO mouse model, the restoration of Mtm1 expression is associated with a normalisation of the Mstn pathway, indicating by analogy that at least partial restoration of the dystrophin protein might be necessary before the inhibition of myostatin. Such an assumption is supported by the higher circulating myostatin levels in BMD compared to DMD, and experimentally by the stronger effect of anti-myostatin therapy in mdx mice if complemented by dystrophin restoration through exon skipping. Therefore, for future trials of anti-myostatin therapy patient eligibility should be tested by ascertaining sufficient levels of the therapy target and taking into account that general circulating myostatin levels may not be representative of the muscle-intrinsic levels of affected target muscles. Furthermore, in the most atrophying diseases, the mutated gene might need to be rescued first in order to restore myostatin expression before inhibiting the myostatin pathway becomes a therapeutic option.
- Golden Retriever muscular dystrophy (GRMD) dog samples were obtained from either the Boisbonne center for gene therapy or the Ecole Nationale Veterinaire d′Alfort. Some dogs have been locoregionaly (single administration of 1×1013 vg/kg via transvenous perfusion of one forelimb) or systemically (single dose of 1×1014 vg/kg or 1×1013 vg/kg) treated with a rAAV2/8 vector encoding a canine microdystrophin, as described in Le Guiner et al (Nat Comms, 2017).
- Injected dogs were monitored for several months and blood samples were collected at different time before the dogs were euthanized.
- The concentrations of GDF8 were assessed by ELISA (#DGDF80, R&D Systems Europe, Ltd, Abingdon, United Kingdom) according to the manufacturer’s instructions. The optical density was measured using a microplate reader (
Infinite 200 Pro, Tecan Group Ltd., Männedorf, Switzerland). - Results can be seen in
FIGS. 4 and 5 and demonstrate that muscle wastage can be stabilised by gene therapy with a rAAV2/8 vector encoding a canine microdystrophin, particularly when the therapy is administered systemically at the high dose (FIG. 4D ). - M. Bartoli, J. Poupiot, A. Vulin, F. Fougerousse, L. Arandel, N. Daniele, C. Roudaut, F. Noulet, L. Garcia, O. Danos, and I. Richard, AAV-mediated delivery of a mutated myostatin propeptide ameliorates
calpain 3 but not alpha-sarcoglycan deficiency, Gene therapy (2007).14 (9), 733. - A. Buj-Bello, V. Laugel, N. Messaddeq, H. Zahreddine, J. Laporte, J. F. Pellissier, and J. L. Mandel, The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice, Proceedings of the National Academy of Sciences of the United States of America (2002).99 (23), 15060.
- A. Buj-Bello, F. Fougerousse, Y. Schwab, N. Messaddeq, D. Spehner, C. R. Pierson, M. Durand, C. Kretz, O. Danos, A. M. Douar, A. H. Beggs, P. Schultz, M. Montus, P. Denefle, and J. L. Mandel, AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis, Human molecular genetics (2008).17 (14), 2132.
- S. Cohen, J. A. Nathan, and A. L. Goldberg, Muscle wasting in disease: molecular mechanisms and promising therapies, Nature reviews (2015).14 (1), 58.
- P. M. Burch, O. Pogoryelova, J. Palandra, R. Goldstein, D. Bennett, L. Fitz, M. Guglieri, C. M. Bettolo, V. Straub, T. Evangelista, H. Neubert, H. Lochmuller, and C. Morris, Reduced serum myostatin concentrations associated with genetic muscle disease progression, Journal of neurology (2017). 264(3):541-553.
- L. W. Gamer, K. A. Cox, C. Small, V. Rosen, Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Developmental Biology (2001). 229(2):407-20.
- C. Le Guiner, L. Servais, M. Montus, T. Larcher, B. Fraysse, S. Moullec, M. Allais, V. Francois, M. Dutilleul, A. Malerba, T. Koo, J-L Thibaut, B. Matot, M. Devaux, J. Le Duff, J-Y Deschamps, I. Barthelemy, S. Blot, I. Testault, K. Wahbi, S. Ederhy, S. Martin, P. Veron, C. Georger, T. Athanasopoulos, C. Masurier, F. Mingozzi, P. Carlier, B, Gjata, J-Y. Hogrel, O. Adjali, F. Mavilio, T. Voit, P. Moullier & G. Dickson, Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy, Nature Communications (2017). 8:16105.
- Q. Jin, C. Qiao, J. Li, J. Li, X. Xiao, Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth, Molecular Therapy (2018).
Feb 2. pii: S1525-0016(18)30023-6. - J. E. Jones, S. M. Cadena, C. Gong, X. Wang, Z. Chen, S. X. Wang, C. Vickers, H. Chen, E. Lach-Trifilieff, J. R. Hadcock, D. J. Glass, Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15, Cell Reports (2018). 22(6):1522-1530.
- Latres E, Mastatis J, Fury W, Miloscio L, Trejos J, Pangilinan J, Okamoto H, Cavino K, Na E, Papatheodorou A, Willer T, Bai Y, Hae Kim J, Rafique A, Jaspers S, Stitt T, Murphy AJ, Yancopoulos GD, Gromada J, Activin A more prominently regulates muscle mass in primates than does GDF8, Nature Communications (2017). 8:15153
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/312,879 US20230273221A1 (en) | 2017-03-10 | 2023-05-05 | Method relating to myostatin pathway inhibition |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1703869.6A GB201703869D0 (en) | 2017-03-10 | 2017-03-10 | Method |
GB1703869.6 | 2017-03-10 | ||
GBGB1713597.1A GB201713597D0 (en) | 2017-08-24 | 2017-08-24 | Method |
GB1713597.1 | 2017-08-24 | ||
PCT/GB2018/050619 WO2018162931A1 (en) | 2017-03-10 | 2018-03-12 | Method relating to myostatin pathway inhibition |
US201916492590A | 2019-09-09 | 2019-09-09 | |
US18/312,879 US20230273221A1 (en) | 2017-03-10 | 2023-05-05 | Method relating to myostatin pathway inhibition |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2018/050619 Continuation WO2018162931A1 (en) | 2017-03-10 | 2018-03-12 | Method relating to myostatin pathway inhibition |
US16/492,590 Continuation US11693013B2 (en) | 2017-03-10 | 2018-03-12 | Method relating to myostatin pathway inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230273221A1 true US20230273221A1 (en) | 2023-08-31 |
Family
ID=61683825
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/492,590 Active 2038-08-23 US11693013B2 (en) | 2017-03-10 | 2018-03-12 | Method relating to myostatin pathway inhibition |
US18/312,879 Pending US20230273221A1 (en) | 2017-03-10 | 2023-05-05 | Method relating to myostatin pathway inhibition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/492,590 Active 2038-08-23 US11693013B2 (en) | 2017-03-10 | 2018-03-12 | Method relating to myostatin pathway inhibition |
Country Status (3)
Country | Link |
---|---|
US (2) | US11693013B2 (en) |
EP (1) | EP3593144A1 (en) |
WO (1) | WO2018162931A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1855694B1 (en) * | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
CA2624976A1 (en) * | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
US7943762B2 (en) * | 2006-05-10 | 2011-05-17 | Avi Biopharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
HUE035240T2 (en) | 2009-04-27 | 2018-05-02 | Novartis Ag | Compositions and methods for increasing muscle growth |
WO2013142816A1 (en) | 2012-03-23 | 2013-09-26 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders |
WO2013188448A2 (en) * | 2012-06-11 | 2013-12-19 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
-
2018
- 2018-03-12 US US16/492,590 patent/US11693013B2/en active Active
- 2018-03-12 EP EP18711665.2A patent/EP3593144A1/en active Pending
- 2018-03-12 WO PCT/GB2018/050619 patent/WO2018162931A1/en unknown
-
2023
- 2023-05-05 US US18/312,879 patent/US20230273221A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018162931A1 (en) | 2018-09-13 |
US20210140976A1 (en) | 2021-05-13 |
EP3593144A1 (en) | 2020-01-15 |
US11693013B2 (en) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7344337B2 (en) | Use of myostatin inhibitors and combination therapy | |
Mariot et al. | Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches | |
US9107942B2 (en) | Methods of diagnosing and treating fibrosis | |
US20120070445A1 (en) | Brain-derived gonadotropins and cognition | |
US20150266955A1 (en) | Detection and treatment of non-dermal fibrosis | |
US9187784B2 (en) | EphA4 is a disease modifier in motor neuron disease | |
EP2185581A2 (en) | Methods and compositions useful in the treatment of mucositis | |
AU2012257731A1 (en) | EphA4 is a disease modifier in motor neuron disease | |
US20230364127A1 (en) | Extracellular vesicle-aso constructs targeting stat6 | |
WO2020210698A1 (en) | Gene therapies for lysosomal disorders | |
US20230273221A1 (en) | Method relating to myostatin pathway inhibition | |
EP3966320A1 (en) | Treatment and detection of inherited neuropathies and associated disorders | |
JP2022513597A (en) | Compositions and Methods for Treating and Preventing Amyotrophic Lateral Sclerosis | |
CA2920700A1 (en) | Ligase e3 rnf185 inhibitors and uses thereof | |
US11326168B2 (en) | Use of potassium channel inhibitor for treating depression | |
Ye et al. | Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno‐associated virus–mediated gene transfer | |
AU2021325891A1 (en) | Gene therapies for neurodegenerative disorders | |
Wang et al. | LncRNA CCRR Attenuates Post-Myocardial Infarction Inflammatory Response by Inhibiting the TLR Signaling Pathway | |
EP3436078B1 (en) | Methods and compositions for the treatment of als | |
Shi et al. | Autophagy inhibition mediated by intrauterine miR‐1912‐3p/CTSD programming participated in the susceptibility to osteoarthritis induced by prenatal dexamethasone exposure in male adult offspring rats | |
EP4253540A1 (en) | Antisense nucleic acid and use thereof | |
EP4215614A1 (en) | Combination therapy for dystrophin-related diseases | |
Sironi | Loss of C9orf72 Function Impairs the Peripheral Neuromuscular System and Anticipates Symptoms in ALS Mice | |
WO2023192116A1 (en) | Methods of controlling body weight and/or energy expenditure | |
TW202402790A (en) | Methods for reducing respiratory infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UCL BUSINESS PLC, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUMONCEAUX, JULIE;VOIT, THOMAS;MARIOT, VIRGINIE;REEL/FRAME:063657/0493 Effective date: 20181107 Owner name: UCL BUSINESS LTD, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:UCL BUSINESS PLC;REEL/FRAME:063664/0794 Effective date: 20190828 Owner name: UCL BUSINESS PLC, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY COLLEGE LONDON;REEL/FRAME:063657/0633 Effective date: 20181112 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |